0001295345-15-000125.txt : 20150514 0001295345-15-000125.hdr.sgml : 20150514 20150514152656 ACCESSION NUMBER: 0001295345-15-000125 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150514 DATE AS OF CHANGE: 20150514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIOGENETIC SCIENCES INC CENTRAL INDEX KEY: 0000856984 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 112655906 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19041 FILM NUMBER: 15862424 BUSINESS ADDRESS: STREET 1: 79 EAST PUTNAM AVE CITY: GREENWICH STATE: CT ZIP: 06830 BUSINESS PHONE: 2032976100 MAIL ADDRESS: STREET 1: 79 EAST PUTNAM AVE CITY: GREENWICH STATE: CT ZIP: 06830 10-Q 1 maba03312015.htm FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q
________________________________

ý                                  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2015

 

 

Commission file number 0-19041

 

 

AMERICAN BIOGENETIC SCIENCES, INC.
(Exact Name Of Registrant As Specified In Its Charter)

Delaware 11-2655906
(State of Incorporation) (I.R.S. Employer Identification No.)
     
79 East Putnam Ave, Greenwich, CT 06830
(Address of Principal Executive Offices) (ZIP Code)

 Registrant's Telephone Number, Including Area Code: (203) 297-6100

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No ¨

On May 14, 2015, the Registrant had 1,088,740 shares of common stock outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer ¨ Accelerated filer ¨ Non-Accelerated filer ¨ Smaller reporting company x

TABLE OF CONTENTS

 

Item
 Description
 Page

PART I - FINANCIAL INFORMATION
 
ITEM 1.    FINANCIAL STATEMENTS. 3
ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION. 8
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 9
ITEM 4.    CONTROLS AND PROCEDURES. 9
   

PART II - OTHER INFORMATION
   
ITEM 1.    LEGAL PROCEEDINGS. 10
ITEM 1A.    RISK FACTORS. 10
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 10
ITEM 3.    DEFAULT UPON SENIOR SECURITIES. 10
ITEM 4.    MINE SAFETY DISCLOSURE. 10
ITEM 5.    OTHER INFORMATION. 10
ITEM 6.    EXHIBITS. 10

 

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents

    Balance Sheets - March 31, 2015 (Unaudited) and December 31, 2014 3
    Statements of Operations - Three Months Ended March 31, 2015 and 2014 (Unaudited) 4
    Statements of Cash Flows - Three Months Ended March 31, 2015 and 2014 (Unaudited) 5
    Notes to Unaudited Interim Financial Statements 6

 

American Biogenetic Sciences, Inc.
Balance Sheets
Back to Table of Contents
  March 31, 2015
 (Unaudited)		 December 31, 2014

ASSETS
 
    Total Assets $ 0 $ 0
 

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
   Accounts payable - trade $ 10,800 $ 12,800
   Accrued interest expenses 53,149 50,310
   Convertible notes, related party 331,681 331,681
   Advances from and accruals due to related party 28,113 18,375
         Total current liabilities 423,743 413,166
 
         Total liabilities 423,743 413,166
 
Stockholders' Deficit:
 
Preferred stock, 10,000,000 shares authorized, $0.0001 par value;
     none issued and outstanding 0 0
Common stock, 900,000,000 shares authorized, $0.0001 par value;
     1,088,740 shares issued and outstanding at March 31, 2015 and December 31, 2014 109 109
   Additional paid-in capital 46,191 46,191
   Accumulated deficit (470,043) (459,466)
     Total Stockholders' Deficit (423,743) (413,166)
 
       Total Liabilities and Stockholders' Deficit $ 0 $ 0
 
See notes to unaudited interim financial statements.

American Biogenetic Sciences, Inc.
Statements of Operations

Back to Table of Contents
Three Months Three Months
Ended Ended
March 31, 2015 March 31, 2014
(Unaudited) (Unaudited)
 
Revenue $ 0 $ 0
 
Costs and Expenses:
   General and administrative 7,738 7,500
   Interest expense 2,839 2,824
Total costs and expenses 10,577 10,324
 
Net loss $ (10,577) $ (10,324)
 
Basic and diluted per shares amounts:
   Basic and diluted net loss $ (0.01) $ (0.01)
 
Weighted average shares outstanding:
Basic and diluted 1,088,740 1,088,740
 

See notes to unaudited interim financial statements.

American Biogenetic Sciences, Inc.

Statements of Cash Flows
Back to Table of Contents
Three Months Three Months
Ended Ended
                March 31, 2015 March 31, 2014
  (Unaudited) (Unaudited)
Cash flows from operating activities:
Net loss $ (10,577) (10,324)
Adjustment required to reconcile net loss to cash used in operating activities:
   Fair value of services provided by related parties 0 5,000
   Increase in accounts payable and accrued expenses 839 5,324
    Cash flows used in operating activities $ (9,738) 0
 
Cash flows from investing activities:
     Cash used in investing activities 0 0
  
Cash flows from financing activities:
   Proceeds of related party borrowings 9,738
     Cash provided by financing activities 9,738 0
 
     Change in cash 0 0
Cash - beginning of period 0 0
Cash - end of period $ 0 $ 0
 

See notes to unaudited interim financial statements.

American Biogenetics Sciences Inc.
Notes to Unaudited Interim Financial Statements
March 31, 2015
Back to Table of Contents

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or "ABS") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company’s sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company’s sole executive officer/director.

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubts about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.

Note 3. Basis of Presentation

In the opinion of management, the accompanying unaudited interim financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. The accounting policies are described in the "Notes to the Financial Statements" in the 2014 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (US GAAP). The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments: ASC # 825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2015 or 2014.

Income Taxes: The Company accounts for income taxes in accordance with ASC # 740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed “more-likely-than-not” to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2015 and 2014. The Company has net operating losses of about $470,043, which begin to expire in 2026.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

Note 4. Convertible Notes to Related Party

On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. On December 31, 2013, the note was formally assigned to our control shareholder.

On December 31, 2013, we issued another convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum and matures after 1 year of the date of issuance or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The maturity date of this convertible promissory note was extended to December 31, 2015. The note was issued in consideration of cash advances made and for services provided to the Company by its sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder.

In accordance with Accounting Standard Codification (“ASC # 815”), Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder’s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

Note 5. Related Party Transactions

Fair value of services: An entity controlled by the Company’s sole officer and director provided corporate securities compliance services to the Company valued at $3,500 during the three months ended March 31, 2015. As of March 31, 2015, $4,000 is outstanding in accounts payable.

An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $5,000 during the three-month period ended March 31, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of cash advances received from our controlling shareholder. Such items due totaled $28,113 at March 31, 2015 and $18,375 at December 31, 2014.

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of March 31, 2015. The Company has no non-cancellable operating leases.

Note 7. Subsequent Events

The Company evaluated its March 31, 2015 financial statements for subsequent events, through May 14, 2015, the date the financial statements were issued and there were no subsequent events that will affect the March 31, 2015 financial statements.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATIONS Back to Table of Contents

Some of the statements contained in this quarterly report of American Biogenetic Sciences, Inc., a Delaware corporation discuss future expectations, contain projections of our plan of operation or financial condition or state other forward-looking information. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such terms or other similar expressions.

General Background

American Biogenetic Sciences, Inc., a Delaware corporation, is sometimes referred to herein as "we", "us", "our", "Company" and the "Registrant". The Registrant was formed in 1983 for the purpose of researching, developing and marketing cardiovascular and neurobiology products for commercial development and distributing vaccines. The Registrant's products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Registrant commenced selling its products during the last quarter of 1997 but did not generate any sufficient revenues from operations to fund its operating expenses.

On September 19, 2002, the Registrant filed a petition under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of New York. On November 4, 2005, the Bankruptcy Court approved an order authorizing a change in control and provided that the Company, subsequent to the bankruptcy proceeding, is free and clear of all liens, claims and other obligations.

On August 13, 2010, the Registrant's sole officer/director, who was also the principal shareholder, transferred and assigned his control stock position to an unrelated third party but remained as the Registrant's sole officer and director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new control shareholder. See Note 4 to the Notes to Unaudited Interim Financial Statements.

Plan of Operation

We have no present operations or revenues and our current activities are related to seeking new business opportunities, including seeking an acquisition or merger with an operating company. If our management seeks to acquire another business or pursue a new business opportunity, it would have substantial flexibility in identifying and selecting a prospective business. Registrant would not be obligated nor does management intend to seek pre-approval from our shareholders. Under the laws of the State of Delaware, the consent of holders of a majority of the issued and outstanding shares, acting without a shareholders' meeting, can approve an acquisition.

The Registrant is entirely dependent on the judgment of its executive officer/director in connection with pursuing a new business opportunity or a selection process for a target operating company. In evaluating a prospective new business opportunity or an operating company, he would consider, among other factors, the following: (i) costs associated with effecting a transaction; (ii) equity interest in and opportunity to control the prospective candidate; (iii) growth potential of the target business; (iv) experience and skill of management and availability of additional personnel; (v) necessary capital requirements; (vi) the prospective candidate's competitive position; (vii) stage of development of the business opportunity; (viii) the market acceptance of the business, its products or services; (ix) the availability of audited financial statements of the potential business opportunity; and (x) the regulatory environment that may be applicable to any prospective business opportunity.

The foregoing criteria are not intended to be exhaustive and there may be other criteria that management may deem relevant. In connection with an evaluation of a prospective or potential business opportunity, management may be expected to conduct a due diligence review.

Results of Operations during the three months ended March 31, 2015 as compared to the three months ended March 31, 2014

We have not generated any revenues during the periods ended March 31, 2015 and 2014. We have operating expenses related to general and administrative expenses being a public company and interest expenses. We incurred $10,577 in net loss due to expenses consisting of general and administrative expenses of $7,738 and interest expenses of $2,839 during the three months ended March 31, 2015 as compared to a net loss of $10,324 due to expenses consisting of general and administrative expenses of $7,500 and interest expenses of $2,824 during the three months ended March 31, 2014.

Our general and administrative expenses increased by $238 or 3.2% during the three months ended March 31, 2015 as compared to the same period in the prior year. During the three months ended March 31, 2015 our interest expense increased by $15 as compared to the same period in the prior year.

Liquidity and Capital Resources

We will use our limited personnel and financial resources in connection with seeking new business opportunities, including seeking an acquisition or merger with an operating company. It may be expected that entering into a new business opportunity or business combination will involve the issuance of a substantial number of restricted shares of common stock. If such additional restricted shares of common stock are issued, our shareholders will experience a dilution in their ownership interest in the Registrant. If a substantial number of restricted shares are issued in connection with a business combination, a change in control may be expected to occur.

On March 31, 2015, we had no assets and had total liabilities of $423,743 consisting of accounts payable of $10,800, accrued interest expenses of $53,149, two short-term convertible notes of $331,681; and advances and accruals from a related party of $28,113.

We financed our negative cash flows from operations of $9,738 during the nine months ended March 31, 2015, which was due to a net loss of $10,577 offset by a increase in account payable and accrued expenses of $839 through related party borrowings of $9,738.

On December 31, 2014, we had no assets and had total liabilities of $413,166 consisting of accounts payable of $12,800, accrued interest expenses of $50,310, two short-term convertible notes of $331,681; and advances and accruals from a related party of $18,375.

We had no cash flows from operations during the three months ended March 31, 2014, which was due to a net loss of $10,324 offset by services provided by related parties valued at $5,000 and an increase in account payable and accrued expenses of $5,324.

In connection with our plan to seek new business opportunities and/or effecting a business combination, we may determine to seek to raise funds from the sale of restricted stock or debt securities. We have no agreements to issue any debt or equity securities and cannot predict whether equity or debt financing will become available at terms acceptable to us, if at all.

There are no limitations in our articles of incorporation on our ability to borrow funds or raise funds through the issuance of restricted common stock to effect a business combination. Our limited resources and lack of operating history may make it difficult to do borrow funds or raise capital. Our inability to borrow funds or raise funds through the issuance of restricted common stock required to effect or facilitate a business combination may have a material adverse effect on our financial condition and future prospects, including the ability to complete a business combination. To the extent that debt financing ultimately proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest, including debt of an acquired business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

We have not entered into, and do not expect to enter into, financial instruments for trading or hedging purposes.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures. As of March 31, 2015, the Company's chief executive officer/chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer/chief financial officer concluded that our disclosure controls and procedures were not effective as of the date of filing this quarterly report due to lack of an oversight committee and a lack of segregation of duties. Management will consider the need to add personnel and implement improved review procedures.

Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS Back to Table of Content

None.

ITEM 1A. RISK FACTORS Back to Table of Content

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014, which could materially affect our business, financial condition or future results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Content

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Content

None.

ITEM 4. MINE SAFETY DISCLOSURE Back to Table of Content

None.

ITEM 5. OTHER INFORMATION Back to Table of Content

None.

ITEM 6. EXHIBITS Back to Table of Content

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.

 Description
31 Certification of CEO/CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 Certification of CEO/CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

/s/ Richard Rubin
Richard Rubin
   CEO, CFO and Chairman
   Dated: May 14, 2015

 EX-31 2 exh31.htm EXHIBIT 31 Exhibit 31

CERTIFICATIONS

I, Richard Rubin, certify that:

1. I have reviewed this quarterly report of American Biogenetic Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the  issuer as of, and for, the periods presented in this report;

4. The  issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the  issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the  issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the  issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the  issuer's internal control over financial reporting that occurred during the  issuer's most recent fiscal quarter (the  issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the   issuer's internal control over financial reporting; and

5. The  issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the   issuer's auditors and the audit committee of the  issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the  issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the  issuer's internal control over financial reporting.

Date: May 14, 2015

/s/ Richard Rubin
CEO and CFO

 EX-32 3 exh32.htm EXHIBIT 32 Exhibit 32

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of American Biogenetic Sciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Richard Rubin, CEO and CFO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard Rubin
CEO and CFO

Dated: May 14, 2015

A signed original of this written statement required by Section 906 has been provided to American Biogenetic Sciences, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.INS 4 maba-20150331.xml 0 0 0 0 0 0 10800 12800 53149 50310 331681 331681 28113 18375 423743 413166 423743 413166 109 109 46191 46191 -470043 -459466 -423743 -413166 0 0 0 0 7738 7500 2839 2824 10577 10324 -10577 -10324 -0.01 -0.01 1088740 1088740 -10577 -10324 0 5000 839 5324 -9738 0 0 0 9738 0 9738 0 0 0 0 0 0 0 <!--egx--><p><b>Note 1. The Company</b></p> <p>American Biogenetic Sciences, Inc. (the &quot;Company&quot;, &#147;We&#148; or &quot;ABS&quot;) was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company&#146;s sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company&#146;s sole executive officer/director. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 2. Going Concern </b></p> <p>The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubts about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 3. Basis of Presentation</b></p> <p>In the opinion of management, the accompanying unaudited interim financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. The accounting policies are described in the &#147;Notes to the Financial Statements&#148; in the 2014 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (US GAAP). The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p>Accounting Policies</p> <p><i>Use of Estimates:</i> &#160;&#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Cash and Cash Equivalents:</i> &#160;&#160;For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Fair Value of Financial Instruments:</i> &#160;&#160;ASC # 825, <i>&quot;Disclosures about Fair Value of Financial Instruments,&quot;</i> requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Earnings per Common Share:</i> &#160;&#160;Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2015 or 2014.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Income Taxes:</i> &#160;&#160;The Company accounts for income taxes in accordance with ASC # 740, <i>&quot;Accounting for Income Taxes,&quot;</i> which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p>ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed &#147;more-likely-than-not&#148; to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions. </p> <p>Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2015 and 2014. The Company has net operating losses of about $470,043, which begin to expire in 2026.</p> <p style='margin:0in;margin-bottom:.0001pt'><i>Impact of recently issued accounting standards </i></p> <p>There were no new accounting pronouncements that had a significant impact on the Company&#146;s operating results or financial position. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 4. Convertible Notes to Related Party</b></p> <p>On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. On December 31, 2013, the note was formally assigned to our control shareholder.</p> <p>On December 31, 2013, we issued another convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum and matures after 1 year of the date of issuance or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The maturity date of this convertible promissory note was extended to December 31, 2015. The note was issued in consideration of cash advances made and for services provided to the Company by its sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder. </p> <p>In accordance with Accounting Standard Codification (&#147;ASC # 815&#148;), Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder&#146;s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 5. Related Party Transactions</b></p> <p><em>Fair value of services:</em> An entity controlled by the Company&#146;s sole officer and director provided corporate securities compliance services to the Company valued at $3,500 during the three months ended March 31, 2015. As of March 31, 2015, $4,000 is outstanding in accounts payable.</p> <p>An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $5,000 during the three-month period ended March 31, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.</p> <p><i>Due Related Parties: </i>Amounts due to related parties consist of cash advances received from our controlling shareholder. Such items due totaled $28,113 at March 31, 2015 and $18,375 at December 31, 2014. </p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 6. Commitments and Contingencies </b></p> <p>There are no pending or threatened legal proceedings as of March 31, 2015. The Company has no non-cancellable operating leases.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><b>Note 7. Subsequent Events</b></p> <p>The Company evaluated its March 31, 2015 financial statements for subsequent events, through May 14, 2015, the date the financial statements were issued and there were no subsequent events that will affect the March 31, 2015 financial statements.</p> <!--egx--><p><i>Use of Estimates:</i> &#160;&#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Cash and Cash Equivalents:</i> &#160;&#160;For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Fair Value of Financial Instruments:</i> &#160;&#160;ASC # 825, <i>&quot;Disclosures about Fair Value of Financial Instruments,&quot;</i> requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Earnings per Common Share:</i> &#160;&#160;Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2015 or 2014.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Income Taxes:</i> &#160;&#160;The Company accounts for income taxes in accordance with ASC # 740, <i>&quot;Accounting for Income Taxes,&quot;</i> which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p>ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed &#147;more-likely-than-not&#148; to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions. </p> <p>Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2015 and 2014. The Company has net operating losses of about $470,043, which begin to expire in 2026.</p> <!--egx--><p style='margin:0in;margin-bottom:.0001pt'><i>Impact of recently issued accounting standards </i></p> <p>There were no new accounting pronouncements that had a significant impact on the Company&#146;s operating results or financial position. </p> 10-Q 2015-03-31 false American Biogenetic Sciences Inc. 0000856984 --12-31 1088740 54242 Smaller Reporting Company Yes No No 2015 Q1 0000856984 2015-01-01 2015-03-31 0000856984 2014-06-30 0000856984 2015-03-31 0000856984 2014-12-31 0000856984 2014-01-01 2014-03-31 0000856984 2013-12-31 0000856984 2014-03-31 iso4217:USD shares iso4217:USD shares pure $0.0001 par value; 10,000,000 shares authorized; none issued $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at March 31, 2015 and December 31, 2014 EX-101.SCH 5 maba-20150331.xsd 000100 - Disclosure - Note 6. Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 2. Going Concern link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 7. Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 3. Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000050 - Disclosure - Note 1. The Company link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards (Policies) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 4. Convertible Notes To Related Party link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 5. Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Note 3. Basis of Presentation: Income Taxes, Policy (Policies) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 maba-20150331_cal.xml EX-101.DEF 7 maba-20150331_def.xml EX-101.LAB 8 maba-20150331_lab.xml Note 4. Convertible Notes To Related Party Revenue Entity Public Float Interest expenses General and administrative Costs and expenses: ASSETS Income Taxes, Policy Cash flows from financing activities: Basic and diluted net loss Common stock Cash Note 7. Subsequent Events Notes Basic and diluted Weighted average shares outstanding Additional paid in capital Entity Filer Category Current Fiscal Year End Date Use of Estimates, Policy (Increase) decrease in current assets: Fair value of services provided by related parties Entity Voluntary Filers Accrued interest expenses Accounts payable - trade Document Fiscal Period Focus Entity Well-known Seasoned Issuer Cash and Cash Equivalents, Policy Cash generated by financing activities Entity Common Stock, Shares Outstanding Entity Central Index Key Basic and diluted per share amounts: Stockholders' deficiency: Convertible note, related party Current assets: Impact of Recently Issued Accounting Standards Amendment Flag Document Period End Date Note 6. Commitments and Contingencies Cash flows from operating activities: Total Stockholders' Deficiency Entity Registrant Name Note 5. Related Party Transactions Note 3. Basis of Presentation Cash - end of period Cash - end of period Increase (decrease) in accounts payable and accrued expenses Adjustments to reconcile net loss to cash used in operating activities: Statements of Cash Flows Total Liabilities and Stockholders' Deficiency Note 1. The Company Total costs and expenses Accumulated deficit Current Liabilities: Document Type Document and Entity Information: Note 2. Going Concern Change in cash Procceds from related party borrowings Cash flows used by operating activities Total liabilities Total current liabilities Advances from and accruals due to related party Fair Value of Financial Instruments, Policy Net loss Preferred stock Balance Sheets LIABILITIES AND STOCKHOLDERS' DEFICIENCY Policies Cash - beginning of period Cash - beginning of period Cash used in investing activities Cash flows from investing activities: Total current assets Entity Current Reporting Status Earnings Per Common Share, Policy Net loss {1} Net loss Statements of Operations Total Assets Document Fiscal Year Focus EX-101.PRE 9 maba-20150331_pre.xml EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#`&='@K@$``)@-```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EUUKPC`4AN\'^P\EM\/& MN"\WK%ZX[7(3YGY`EAQM,4U"$IW^^YW6#X9TBDQ8;EK:Y+SOTT!?SND-EJ5* M%N!\871&6-HF"6AA9*&G&?D8O[2Z)/&!:\F5T9"1%7@RZ%]>],8K"S[!:NTS MDH=@'RGU(H>2^]18T+@R,:[D`1_=E%HN9GP*M--NWU%A=``=6J'2(/W>$TSX M7(7D>8FOUR0.E"?)<+VQ\LH(MU85@@8DGD'KK M@$N?`X12I?4]+7FAM]P'_.O-GM8W=F:0ZOMJX1,Y.I%P7$?"<1,)QVTD''>1 M<-Q'PM&-A.,A$@[6C@4DED1EL40JBR5362RARF))519+K++_RM6`?2?0^OKW M'[>6.=+X^+!2X,\<5FO18\XY=R#?@\,._>P`/[6/<`BNQ##'5O7,A[#3/>2/ M_?/(&>MQDG!P.L!V5*BJ6Q:%P(4"=L-"4].]<\0IY'3#O:X?JCE'@FSPIO5< MU?\&``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O M+G)E;',@H@0"**```@`````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ M;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B]. MP[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4 M_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^^CSY MLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P`` M`/__`P!02P,$%``&``@````A`,_C$;6&`0``(PP``!H`"`%X;"]?VX./`2:):F,ZK_YB#KBYS)MLB)WA:N_N[8N*4&_E#Z8"L"ZI%R78'/B0X:>=A8CIYC0ZV+8.+(:-D;E!(5CG6G0@SDM MZ>G+,!&QD:!$,A;2(,$;\53Q6O94?`A#,@\IPC=H+\*'SCT[Q\2P++(:EJ%R M8L-A*)W8<'`VL]A6S3"K,G<9A#M[3<4U%&]6NZO%]+U\$<;4!)UL/T&]$!\Z M#Q5ZZ,4V"O6)14>#LIF&[!KORO]&3=&NB:V&X7*"CM0`."Q%Z2Q#>F7LL7'/ M0_^T^EUC]2#;UXVJ]_````__\#`%!+`P04 M``8`"````"$`*RY&OG$"``"(!@``#P```'AL+W=OT%54N!HV62:6N1V%G;I?3?,W;5[!0"@E/J M.//XG9EWW-'Y21:6P;EI(!\68]7"IMW#TPFSJBXTL<7?023HLGC1)SDU4P%)L M2K?`]`YTK%?6S;*^_]*7XD["UOX/\LOH^5ZJ0F_]IUC:7;/JH(!MV+J7A5OC M?I(DS;L_(%=K=WB)^)CP0P7QG/",5$CO4!&.G>)3Y:3;\9G:5U]J;*&O^@PS M2UEDAA)_F%F1>N&4\K,"(W.A^(74*U#@9,YORR,4%;D3E(,;>R@%=/W9:RD\_-G@]U0 MG<,*40QM;)JT;!PK\-#?,3YDHGYC(XRWH)$ M4#!R',8!+ZIH/X1KJ!NKY^%EL:'/Y')"P```/__`P!02P,$%``&``@` M```A`,S9TI!@`P``^PH``!@```!X;"]W;W)K"\O'[.!\;SA[<\](YSXX!#H1?NSIARYGDZV?&0&1C50Y,W"I MMIXN%6=I]5">>4/?'WLY$X5+#C/5QT-N-B+A3S+9Y[PP9*)XQ@SPZYTH]=$M M3_K8Y4R][,N[1.8E6*Q%)LQ[9>HZ>3+[LBVD8NL,\GX+1BPY>E<79_:Y2)34 MRQ121)-'=%FX,.V0A(;VO"ZC^[GW"A5-:LGJ7!)T%?%1 M@8T`N@81\FXC7J[YD03%2((]0+05W0#O!FUHK7NN&$T;28<$"M2?!,70Y];" MTR:C*.HB8?6I@DXZI3=X$?329=06P)PN&H M$73`8'K;%<'Q">'MNMTC?*@+./8;>P(DR:@"M&(QQ0@^\OU3N$,V_A\R?,@B MLZ9T11(BNP^MCL84K=FN5FW29;M=+11;3-8$KT@RH79.)Z'U[L7M^)5RX9>J MM0_<1D*QA11:#23)Y09>CG6Z-^WB])LK?,C".HTMS15)J#\7"D5AF[I#%L!X M]Z]4I;:8[)>QUER%JN.WJ7#S[-V_@+;:]A8Q'EL-K#4T5*>AJB1KH<["+A_MH?B7;C#I+U9JW@T($S=P7I99I)Y%[/$<,X5UN[C9GG,`P``,`T``!@```!X;"]W;W)K ML@*^27B54PF7U=$19<5HK![*,\=SW863T[2P-<.FNH6#)TD:L7L> MG7-62$U2L8Q*T"].:2D:MCRZA2ZGU>.YG$0\+X'BD&:I?%&DMI5'F\_'@E?T MD,&YGXE/HX9;70SH\S2JN.")G`*=HX4.S[QVU@XP[;9Q"B=`VZV*)8%]1S8A M6=K.;JL,^IVRB^A\ML2)7SY6:?PE+1BX#7F2]/"#92R2+(;,V19FY,#Y(S[Z M&6ZY$$0H``81?YLP=QY&<=HPW<]-R`>5MF^5%;.$GC/YG5\^L?1XDA!I#C:@ M&YOXY9Z)"-(`L:;>'%DCG@$%O%IYBO4$-M)GK2Z-Y2FP9XOI?.G.","M`Q/R M(45*VXK.0O+\CP:1FDJ3>#4)O%]J$C*:9%:3P'M-0H#O;06./HTRZIY*NMM6 M_&)!F8)>45(L>K(!PL85?8;6I__9!/X@R1VR!#;T%S@@(%=/.W?K/$$VHAJQ MUPAX;1&DCP@;!"84Q+4*X6Q=A:_GJQ&"8!2"^4-E>WVC&]R[(?9:T17R*J/"!N$*60Q1@B"^T+6_3![C9BKNO4]=VUD*M3? MJTSU$K,<(P/!?1G$[!$-T88<7NNBL$&8AN`O6Z>+W^X1!!M*C%[<:XBO-*SF MB_7*M*0!F$+68X0@V!!B-.=>0U!(LIM,B#>9@=0$!\R$&&D,&ZRIB<`/3-<= MG'$SN/>V2^HI0]UU,.@6KC$+Y1-Q5ZNE;^0TK"'#XB$X[V[.F4(;:HR<[&M, M9Z+4=Y9*W]SW_*N]O4+&WX\16O3$[,X88@X9Q1C8W>8FYIAI,8.$X22\W1H] M-WMRS%%#FMEZ'7K$'#8M9B`'Y^'MF1?:75,"V%E+(%'W>D2TE#IY55?2%ZJ)>[`)2R=ZN,)_IDPV'W<*8`3 MSF5S@974_M?9_0,``/__`P!02P,$%``&``@````A``0>IBJ<`@``L`8``!D` M``!X;"]W;W)K&ULE%5;;YLP%'Z?M/]@^;T82-*F M**1*5V6KM$K3M,NS8PQ8Q1C93M/^^YV#&Q*:KNM>2'PX_FZ^L+AZU`UYD-8I MT^8TB6)*9"M,H=HJIS]_K,_FE#C/VX(WII4Y?9*.7BT_?ECLC+UWM92>`$+K M0\FEW$DP3:R48ZOU8(28G8.F_T[]"4]*("5B_MAGN^7%BS([#< MT.TZCILGR0!XKRD@#"K_)A+4(<@*47(*^Q3X'03[L$R2>,$>(`WQW',=>N!Y MZ!DZ&*@9)(&,8TFOQ[-GQF9DQKA0RG4H'-.DK]-,_H<&FR'O8_'Q`3QG^F8""-.<<7>-H:S8%&.C21),E@)E,]-\#.$.C_(&J4*A.]/%9M[\B'6 M4#DU=SZ&17.3"1R-M\WAK#%^J(R,3`:S(R,78\:WB;!Y3!0JIT;PDGUY$.)_ MKA+.&N.'RLC(](61<$.$8ZBEK>0GV32."+/%TY_"^1FJP\6T2G%?O:Q/LU6_ M]=GP`BZ,CE?RCMM*M8XTL@3(.+H`)S9<.6'@30>ZX=HP'JZ*_F\-7P8)1RB. MH+DTQN\'0,R&;\WR#P```/__`P!02P,$%``&``@````A``?8_6IZ`@``Y04` M`!D```!X;"]W;W)K&ULE%3+;MLP$+P7Z#\0O$>4 M_$HB6`[L&FD#-$!1]'&FJ95$1!0%DH[MO^]2C&4K;H/T(IO4<'9FN*OYW5[5 MY!F,E;K):!+%E$`C="Z;,J,_?]Q?W5!B'6]R7NL&,GH`2^\6'S_,=]H\V0K` M$61H;$8KY]J4,2LJ4-Q&NH4&WQ3:*.YP:4IF6P,\[PZIFHWB>,84EPT-#*EY M#X,"B8&:.]1O*]G:(YL2[Z%3W#QMVRNA58L4&UE+=^A(*5$B M?2@;;?BF1M_[9,+%D;M;7-`K*8RVNG`1TK$@]-+S+;MER+28YQ(=^-B)@2*C MRR1=S2A;S+M\?DG8V;/_Q%9Z]]G(_*ML`,/&:_(7L-'ZR4,?HB'O*\T/:[`"`T6::#3U3$+7*`"?1$G?&1@( MWV=TA(5E[JJ,CF?1]#H>)P@G&[#N7GI*2L36.JU^!U#2B0I-QBL,^+)!G-V3.F(5XP MJX#!YPG3(QBJZ26AC'-)?X_G6-F#?64?EY>R"AOG94Y"!F7&_U/&@S&9<_'Q MB3=4#IA)%_>YG\FPT#'BMWWY0W@GYSZ29-P'%BJ^@/"GS_1FVF,&;K%#WA^J M!W?%^U3#SJ6WV9#6>YMA^[SMS1\:TH>=@8_9*Q]AK$+O*C`E?(*ZMD3HK1^9 M$39=O]M/\W+D+^/U_B1==E/.^A`?1='""ZT=L<%%F;]!WKQ!P``__\#`%!+`P04``8`"``` M`"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84 MOP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[ M[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B M).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%! ML#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90 MC",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^ M8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX M`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%' M1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW M5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\ M6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^ M4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X# M0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W M0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC M&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#> M6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\ M]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6 MTT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[ M]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V M6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PD MU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0 M"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$ MO#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+ M&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+& MR0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[ MMM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO M!KWUQ MX\2+PK'>N6WKFALZT<(+5V/]+T_6S4#7DM0.%[8?A>Y8?W43_?O)5[\;)>FK M[WY^=MU4`T28C/7G-%W?MUJ)\^P&=G(;K=T05Y91'-@I#N-5*UG'KKU(J%'@ MMXQV^ZX5V%ZH9PCW@2,#$MCQRV9]XT3!VDZ]N>=[Z2O#TK7`N?^P"J/8GON@ MNNV8MK/#9@=[\('GQ%$2+=-;P+6BY=)SW'V6P]:P!:3)*-P$5I`FFA-MPG2L M&\4I+;OR83'6[W0M4WD6+4#BC__>1.EWO\_^O/OVW;OV/[_Y[N\_NXM__/+U M_K5?OM%;.S$<)GQP&O.V?1(6ES/D5J[!9+2,0DX1>)T9Z/XEC'X-+;J&8(!Z M=-MDE/RF?;%]G.D0/2?RHUA+X67HQ\Z$=N!F=\QLWYO''MVVM`//?\U.&W2" M!49^7^#!372RE4FXKIPYL=GI-"`:@DY=.L/K%$`EFTZ>ULG^UP&=!%F]:EGG MV$^0Q;0XK5=CLO;C8L^&Y\@J?,7)B5?SL6Y9R"&==IO,RCOL0L*&LS;D74W8 M7>]JFG6MKM5O5#,A%O?]1@*[5I.FK!!HO>\_7,VAJ_5`ZC#-6M% M#UWW1/_N6_2Y1IQ<>4!KU&.8P*7O?6\59L-MLEEC1N?$WCHERQTR[R6T/>;* M9F6Q&4."L=CS_6(JUNW29`5G)B/,"E,W#BT<:/GWI];D\@Z9MVM-5>Y5CH,BK'`-%7F5SZE8#F3_O*5A>4-Q7.0:*O,HQ M4.35?L,9N*_Y1B<[5567:&>FT?Q`E7K;G&]TT8ME9V;C'QWF:)RB[W5,_U-HS7^ MG4=IBE7[R6CAV:LHM'U\;>U:[/Z>:(GG&GB$,=;39\]Y@3!AK32;8V^Y=)- MB[R0NT^R!7,U\[1D`\3$+B0D6S2A8[F,*:LCUT).1ZZ!I(Y<"UD=T74.=:Z= M)1?1!H_4WCK8L@;M-JN.:L?+84".^(&(J6RS;\_*)@(X?C M^OYGRN5_6Q;#!U8N)J/MDGN(BF><])21GM'25RP/YE^SH2([`,=CC8RCC31[ MO?9?/VV"N1M;['$W$\'.TC)D>31E8UQYS-9L`Y>MO>@9S$]QE+I.RA['LS7B M8WRZ1_ATBE(/*"6AY+OY!_0DM+2+]GF9G+MPCTTLPX.$'@+)''4JRJ%,.Y M'3VM-`$.3IC`PJC;S)#7.9;SE1F$2[K@4%H$:>"419J+2B[G0F9)X+1%I@W. M0[B@H%2DF@+H**'`.:*C:/SM\!P4CT(8(15Q`!\E MO:*<)W2$$>.*9N`HJ,J07#08JE(DST%5CBQ=8:A*D1P%51F2]X2J%,ES4)4C M.5>H2I$Z%XX1;;X9=-L$95; M/T6I=7PI%`[:E?]O?;5=5BZD=HX53<#:-<^JIZQRA"]8+<65TO33%)OVN]+: MJ?8R1Q79YEH(5G$KY6/+6 MM3K"&[?/&5PD/%UAB$K-65%?N3#_)C+$Q>W*"*DD08L[JCE0MU#-@?R=*"Q`1E#,/=` M4WR<60S8&OW6#;\_;?]!N]'>.S3F(05F8R=1G6\\'SO/:"2FR92S2;"98YJ= MS(>_4UB8>&18!I5('!:JE;I80,BQ:(+-82&\ZF)!?(;5I>E9B85GO;6Q4/3D M6%3^<%C(PG5YH4F.)=J^)VE[\Y`?V4)!R8M4EN'%8Y5^I#*3PX+*=;%*/U*1 MPF%!Y;I8I1_!D,,R(:0N5NE'>(''0KC5Q2K\:,)Q'%9/TO9W!_THQBK-ZF5X M\5BE'\58[4K&*H]5^E&,55*Y+J_2CT#E[&7B0EVLTH]BGC`E\P2O8^E'T?8] M2=N_S:ABQ!N2$9^AE+[#-\Y&^,&:E(TRE-)K8I1W):,\0RG])<:W*1G?&4KI M*>!Q&IFX(./U#*7P45>TKBEIW:F]V&5=,6`,29/@307.QL<;)")Z_P2K6O%Z M`UXA6J.446CV[#HOV@R;D`H@L3_0,"H#]+A=^W9HIU'\JE&E6L")3N])POTI MB@H;B0@&#F4(_8"W=>!%(!KLDEE(C&&J$.K`%'U!-`\]MJH#@]89&S'^J!BH M`X/6&8R85&G^)`/S(5QO"@^)N92&;AF(CU[XXB[$R!$M;("D#-(G=Y/&=A%_ M8I4WF?#-C@6]0#,NW"7]L9/GXJ+8[W\_F>V[1O!E-_UD_#F[,KMN[&?:F M#S<]+"&;:,]^R],1B__N+C%3QQKFQ._G-Y M;JQS!QE]MHD6M+&[=*=$*RE>3C3Y'P```/__`P!02P,$%``&``@````A`%5U M)#5S%```)"N?YC46V`7R M+'F4>9+]G5/%2[/9DAQD)P;F(I&LJE/G\C]7O?S#IV5BKFU>Q%GZ:C39W1\9 MFX99%*?S5Z/OKLYWGH],409I%"19:E^-;FTQ^L/)O_[+RZ(H#6O3XM5H49:K M%WM[1;BPRZ#8S58VY5G$)R_+D]=96"UM6AK(,&_2,BYOS=O4[0_9 MYO%WEZ_-HR3L3G8GQSW7_Y' ME?)R7U\>]5_>0\Z+_O>>X@]V'A=E'G"/=\'2]K\Z7=H\#H/4?!5G]K\[J_*<;\QY7(1\]X,-\JTGUGMFRR7BO"RS\./8 M7"Z"G*N_KTK5/Q2R?X1?=E%-$YAUGF1!N>63\SBQN3GCLO,LWR#U+17[`CDI2`H35=:4V=W+ MUZ^?Q,$T3N(RWB3+?7C'!Q>YG5FL.<(38)I]'O[MKW_[:__9GR?_U7^$38EU M#V[QYX.-ST^C"&JS%!&N@EBX:\)@%2/2_L;(J5I6CI&1G<5AO`$#[HH*+(LL MB;"XWYK7^BGXNL%X]_5_MAQ3YC]T]:/]W?W]_8G(U%P'265_;R;[8Q[)OZ9P MJ!94Y2++X[_8Z/>H0FI-+$8<]:\VN->=FTW&^\^?CY\=[?L=E?2LQ5`3E`;7 M%RX:WZ=?8'IV.04#O4?<,+\'F;G`H!7/49AL9MZO;!Z("+<:?-<';YRX;;,^ MCS[8:YM6&U;Y-3Y4')3$#$&TC%-UOF5\O?'EV_OLUEM25G`OV6Z;?;^SI4FR M8@-DO@H*_).LC.*D$GO'O3_LR_YE_PXQ"#2*<[S9*H9U3K??]P\_#V*OTB+> MPN;7L<#3*L^N8R(L,[U=0Z0!J"&.(1`LK'D<6??3$S%L<$VBOA9I56@>5K=Q M6^F(W$R$QVS=7";HMWY).-FSU`!1^7[#GR0=1H;'[Y^7_^9'_Y^7]- MEIO1Z5>7HR?F)BBX9ICEA%S*(>[\&F]X0]!G)`BT*Z!$$(D0??*[YX>[YH*; MYN+V0E1(KA\+SK0@PPYD%@=C(Z?[P_4*P M%#K?V1OS0Y9_5*+>9=>.;4=*TO$Z-P#G7#BA$<7:P6RNZT^K>44(,SG4W(<, MJ,/,7W[^[\(4&=%+-L/-VGPOBG,;EB(5\IK"!PEJO$41SR4X7<0%21ZY0I8X MUV]66:&.7209I'"C-JER$><^%#+3JD1.DB.R!ZHR2(7]9$,$<[U)ST:RI,I^ ML&N^SD1Q",2@/NU9C:2S+XH5TGXU6HF2Y-=V=#*XTO26GEPA,4$Q31OD"&_M MZ$S1.L5%`*U3:U,4R1(?Z-V*"NHO7>82;R,!05A:E;E MXC.0_:K*"7F<0YW-4"-N.:TP;-D$3D[!2S%%)0F7P=U=1%B8/(AY4%13>`N3 MN%6455,Y;$JHTR4:NES<>ZO`<0]+V710;E$F\;K@55)AH62&A!0_8B+[@"KE0IN:%.A=H-_(J4>/R=E@G#P4`"KZ$V1>B=*2%H$H%P#J@5%,T5 MK6R5U"EDW*GV>)H]G,.Y;RNR)YM#HDO(Q7V<0RQA]\ZW!-Q9E1";".X'NHB[ M_8A<%.9OXG*A^M(2V-"-ZD"*(,\::]$$%+A+!3IM3M.4S&R`@C\J3V276RF! MB/E0=NF'V^Z:<@YQD#!WE5'3(()"HRQF5X1Y/%5I*D$XU'=*!G8D6Y^[V`(" M+ANT$7_K/1XEKJ.[*)1[5JM(_##\!Q!J>8[=#C"Y8:BC5.ZR(^'%U&?V6MLS M;!$(MHD:0ZUH@V*B1&7@$":/^+F4>'^<(,^\+ZJU=4@,8_4&4<:Z-2M$9R.* M2T3<@!6@8'^J<$<:AG89B:Z&\2KA"Q>.)2@*[R6^\#J$LTW55I1YJI`^R)%* MA?GZ]/3BB;OVH,HV`BX7N;6&)%>*CD[0_50+8X;1A; MGR>,%#G/*BZM>L0#>2A0E/$&$&[IRV6G;AM>SE6NDT MEZ+K=^`8EOD&$*",:PM?UN2=_'/!?XJ_2'Y+\78RVCMY&6:)(W*)^]0G^3F< M<)^:-G8N@=XPBR7AWMZ@E:8-UVRD8K#%>Q`T_"B MBI?K(-.Q84P`@X=7N*!;/"OV/J`'PPKC5:HP+=:*&UD&'ZV1O$$9HRA!=:E: MK@12)%;!'03.I4$@7A!%"Y8NPX&EKA*ERSI%%_V]U6>Y#W0+%HA(MZUQSDXL M5Q:HBC10T#!!MY9W0]34GE\_JG,M"DP*\>TBQ23--7;-:5@*UM7*"68!L%', MC5%*J57)LH8_7O]0F*8VS\_EB>8H@CSZPQN,%YW@KE^UKW'4# M;6L!LW.C`)TH!<`GSB@O=[#.)1$:`0.&D-#TT/*69*(NGE`EI3I$F@>;43*$ M(84[)^(.QD`8N*;1%/Y-G2:/]/\"AIZ?VP2@Z?SW4J&2C5L7\C8EM]"&RQQ8,G_/R2=C,B]&J?C`LX'<'(\VB#X5R!V.*7! M;W6M/TCVZE5RQS=K?!+G4 MC+@L*$UU1#MM4HS^TAR[JY;6%5(E5XOF%+0UF-0"JN2)+F>^L9)XB8>EMT(V M:M)*RT;H!*&G=AQM>\!I%\IE/KA0;\+K:BCB>RNY-':K?VD]J]3SD< M.ER)^JWB:$BEF*-TW=3XII8>=YFAO[9X-+'?1@8T4B^"ODD"I M9:L`K:3"(E!"E$%T*T0*U$OOGD?:G-?)R008M MM']FD-%)TH3F+J._J%#B9A'32VP""JI#V9QDVAMX'1)(HMUA>MU0YV*8>L5P MD;3$P83V*U[@`,FF:KNJ^_B:_0H^U2_:,WS9$L$:JH]:42RIDE-+KL,&6@K2 M;Z!0Y=(5-UTCNZE[W6%/&A`19=!OZ#'@@"4@%Z2BK^PZX!T*\4:\O']WG_%-"9_F,(.^!-O38>N$06P\I<,T MDSZ(5!4D>W-4*(!0[TJDPSQ@O.6)*+ETB9DF`)(2ZI8SR3"$N$XN+#SNE##% M6N2&=0U/R\6P84X&H_:S`O2T4D7=RI0WV0[=BA50F$E]4"`\LI+\$-RYDS0I M%O[*KOXN\AGPYS5)Z";1Z1Q!]M$B\RYITT M+X]+5UUG5<%JUV!0]V0_09HD7/83)8JZ]OS69=5KQW+CR*(:D32VEEEN=_24 MVQU.2'>0A)3>W"V:,P:H9QO8#?X0*6NP?`=_.KQI&*/20%YM9-YD_+Z.[T)% MY:_X$*B/11A3DFY0L6[F-I$M""0*%@D3Q*S?'^;TA=&]XB MPEI3G=*Y0)_ZKHN-F;TI$[6FVAU*R($W;+1K7;'X[2.L0=^%IAK&!2'0=1&& MAP=VXQ?!!&E`-!4P.$D_[IBOI(4DY644-^M*5K;6%MO,1LV<@/)/M_^1E+N@ M+J<5'6]`[61AV_>H>5M3"!/%$GT;DUJ/M@J:29;4F6< M6(=#*=W+#N*`%2F5,J91V%@T$AXLJ-L'1AJ*@!0CDE0X/06N*>*9K^W)E@5U M>0H(:RVD1J[^15V;[VA76H,$J&Y&ZYV6V*\R\\&/:5T,C6G)5V9P)1IWY\KW MJ7E/]U2:W'2M45C:R#?(PO/2!\N.%OBRY`73BZ)@39>XM?!'SY[J@!&'2C]B ML$VKMN?63]5DM%*LUEZJH8F?$KE.#GZC\6]`5V.)C9:QG\*"F6*02H(F"7Y( MH]D(`W`QOJ`Q3[,FS7%`ZF5%7R[LS(-)K!KXA1IDN]0"2G0"BF$J>*3!;N<* M.D+@>(7Z:A8DIES''EH&"^H9NB6#>VH]XM*DM;L^N@*=7:#QN#/(1#&A3#L8 MZCL[R_12VNI.Q`:57C=N=F]KG:6#A_V:C?6:ACO:ZL2APFC:%\KEIGOFIP9` MIGT3MC,LU*_I^SO7Y[6B&7YLIBI%189G"IB#AKNY"YO`B/4I2Q&_2@![I0L% M".%(W="!EZ9`"\<*#8,"Z7?A0,=&N65W5$4F@];NKVDCOL?.NF8L]:[$9QQ',Q--/ M?*_)F6[=91!\TFCOGP$&!\=]+/#U<4)Z#U[:>+^+K2);B?:T%0LG^W(Z_M5` M1J*98>57<)6\HI2V5:W%8"K0M!7?[X2F%9V>.*L4GP=-HJ_!V+HXYK74N&T= M7GK_CL^L-.=(]6.T!57\_@[`X)10#B2/[H1*[N@]X)PQB8TW6LOPLW M7:-%LX0H6%(IA!-)4!6,80M[72:`(Q$(0/F7I#7,4FG1M(4%M*5-86X6#I]D MQ8S8F'RQ,#_1&HMG@AG;4Z[YK(BE?X'78H$ES%3 M;35+5.DJ2DX2_`YQ'8+:\*A#VG"$A&FLA33F2@:_B`:E\[FN0-KDZ[0'<.:U MW_V22LZG6XQ,A-H-++MFJMK:S+ZIFDE8WTPS'6DX2#S6K0ZBWS[8;KH>7M"( MJ^G/4AZXGRMUN+`Q"_B/Y,>Q7J+/CQV=L?"EUJ%)"X8?79XC4"_952[R$9/T M4433Z!9D@$>4H1)7._$(T*32$@[[I$*:^^SAQP=4"=8GR[4"(W_YT3,>,87A M5$HJVUV#H@;S8K.U^2MT"D]._8#"P)^62&$(B)2!,.'&>F`M*2!@[HOJ=P8E MBF\,V@"M[A3^F(.%CPZ>CR>30]'_@6SWT>3Y^/#9L;SM^^FALG3I,KFGDLDM M&?EP::1(^:R>II"QJG6HVB*<=Y)HW;?3EO0V<.4-"@^1N#0-E;1^(@.M"8.9 M.DP<4@_@M:H5G%V_OHM"/`;5@YKB'DB!0_X.S!5-VY2?FN*&YGEV/!/GTE1' MWC#K.?"G4"W@=0IJ$J&LD]7)IALC<67:3@%&QDG+0N+I/*OF"[:X-1,=29[X MD62-UM1S;HY6^#YKG0@C/#[LU`PV#N(]^J%CLW[P1G9^`-T]0_7L.MPRE/G" M]*>BQD9'J&[-XWJ4ZDE/M4[J%_WGV[;J?Z=:N)VB,YGG5?V6']ZT8Q\/(.W> MM9])BWK[[^^<*'D`59^QRV?2U_3`+TAN!!^(6"^E._P`JNY=^YFTK'5T[M>B MH<\_]\2F;/>A+MN]=>633HA>A_7\L5"MN!L:W=;_'K)12^4>?S-^\G\"```` M__\#`%!+`P04``8`"````"$`/S/&K1$#``!""0``&````'AL+W=O,,@VU`DKL!'B":7?3,=`?]L-K33P#U,7W0#5= M+:78.]`T<*1J*;9@L`#C8V`&HP_UO4@A1#2Y1Y>$0+=#$`K*\[R:S);>,V0T M.TC6EY)@J$B/"BP$T/6($/GP<46SA6!=9&,NUPXGALM4XZV([\$_``:GH+%(HMJ+%5'",Q4.%L M?&J)KG;I<#N<]':W@*'8`IM:8$82A%UKC7S7MYZ$]`/!H)`P M76Y(6:>VT*Q2K0^:8RUGLWARZFQ3S0\E!L^,+/-*KYGO[X*X$$(?+_"`_M_/ZC\```#__P,`4$L#!!0`!@`(```` M(0!!F^LZ#04``'43```8````>&PO=V]R:W-H965T&ULG%A; M;ZLX$'Y?:?\#XKT!`[DJR5&Y=/=(9Z75:B_/E#@)*N`(:-/S[W>&@<0V'$K/ M2VG&WXR_SQYFC+=?WO/,>.-EE8IB9[*9;1J\2,0A+4X[\Y^_GQY6IE'5<7&( M,U'PG?F=5^:7_:^_;*^B?*G.G-<&1"BJG7FNZ\O&LJKDS/.XFHD++V#D*,H\ MKN%G>;*J2\GC0^.49Y9CVPLKC]/"I`B;Q/4-/)D\_54B#)^SD#W._/BI(O= M_.B%S].D%)4XUC,(9Q'1ON:UM;8@TGY[2$$!+KM1\N/.?&2;R+%-:[]M%NC? ME%\KZ7^C.HOK;V5Z^)86'%8;]@EWX%F(%X1^/:`)G*V>]U.S`W^6QH$?X]>L M_DM#9!9G//&>^7#51 M1CS=UA.>K2>S[]./.'JM(SR[*;V9LYJS^0*)CWC":*,8GI.FM&C%F@T(XSK> M;TMQ-2"K84VJ2XSO"-M`L&[E:>K;7OQH*V`/,,@C1FEBP2I7D#]O>V>^M=Y@ MRY,6XA,$WM@[1$4$'0+W%Z.&G4%R6:@^40?![`)%-UFPB;*LX43JV",84D:F MME3G\0GB-0F#W`+=$.J&2#(HU&">Z=00O#,AU'W55AHU@BR;5;?5L8#&[K3# M$7`D@17"D)W3"2-8([Q62?D$\08)=V.W'.@,F%.:NJ@;TS@Z1 MY*"DQO(SQ!&L$75KJ!#0N$5<I[(W7!P1K MQ%V-.$&(N.NRQ4K;DH``$O.//"+)0Z&^5JECQ7:AXXY+0"=-@J=)(`A)<%:, M:1(#&I<4R`YLY2ZUBA])#HH`!FRG+WZ#UJAK,_DMAKA[CKOT=/(M0F*O^C#8 MLUYO09X[L_%1!6#7F9P]C'J47,-=;2J_Q8P)H"BR`+*T/H,")!]5`/8F24#3 M]9=XMOH@C1@U-46+WBI;#!3G6\]RM9X5M!C(D#M&>]?#"7&B\3BJ9FQO/Z69 M^J*LV=/*C,^ZWHE5G]F:E*`=EN5Z6H$(QT-$XR%4I=@7):7CE8%1%U7DZ66Y MQ;2IMF!KC7S0`N3LI+`_=(ED%Y4^=LGI]*FG*O2UE]_'3PEXD8G+@[>T[7Y] M((@L0'6:K[U^@9"<5`G8+Z=+H.ZJ2-"+,Y,[],-PB9.:='M^5IT&2X3DI$K` MSBE)F-9F&/5;14JO6!-F^,#:!I#W800>R7"5/G9/B?X'[P#U6F@)W3'.9SU3 MT#>%?5.DF%1.V!`E3C_[K45]55YC5RLX/B,,MI5;@?6TIA/<09WJL&^*%).B M!VX$>GKP)/+);\+HMQA5C]9X@COHIJ=OPGL,+`80ZG8*IWL)^BS. M>7GB`<^RRDC$*]XYS.$8?;/2?8C/-O"U"OZ:/81[DB'[(UO!P&K``W8*1M9# M(X[=7;I8MVG@TN,2G_@?<7E*B\K(^!$(VK,E%**2KDWH1RTNS>?XLZCANJ/Y M]PS76QR^7.%FPC2.0M3=#UR&VX79_G\```#__P,`4$L#!!0`!@`(````(0!J MJSC=3@(```4%```9````>&PO=V]R:W-H965TNCP3:6T9!:7N@Y-KX&5PR'9ADD4 MS4/)1$<]0ZK?PZ&J2G!8*;Z3T%E/HJ%E%O6;1O3FS";Y>^@DT]M=?\>5[)%B M(UIA3P,I)9*GSW6G--NTV/MOS8_@8(E.1 ME0([<+83#55.%W&ZG-*PR`9_?@LXF*MG8AIU^*Q%^55T@&;CF-P`-DIM'?2Y M=%MX.+PYO1X&\%V3$BJV:^T/=?@"HFXL3GN&#;F^TO*T`L/14*0)DIECXJI% M`7@E4KADH"'LF-,$"XO2-CF=S(/9?32)$4XV8.Q:.$I*^,Y8)?]X4#R(\ER# MM!6SK,BT.A`<-Z)-SUQXXA2)G:8)=N891I5OB41UCF3A6'**.<7C!HW=%W$T MS\(]NL'_898>@]<+9D2$J&:4A#*N);UNS[FR`[O*SBXG9>DWKLLDKY>9_$\9 M!T9GKL5'%UY?V6.&`+WH9_JRD+,XF;TY]W-C[M0PZXM=T?W8B:_H,3'>1M!# M-&*\"!]'/W,)NH9/T+:&<+5S48MQ6./N^!4LDB$SXPM,8<]J^,9T+3I#6JCP M:!3<8Q/:Y]@OK.J'1&V4Q?P-CPW^;@#G$@4(KI2RYX7[4L8?6/$7``#__P,` M4$L#!!0`!@`(````(0#0F'W>30(```4%```9````>&PO=V]R:W-H965TAZ32PHC\DFW`21?>A9**EGB'1[^%092DX;!0_2&BM)]'0,(OZ32TZ M,[!)_AXZR?3^T-UQ)3NDV(E&V.>>E!+)DZ>J59KM&NS[',\8'[C[Q0V]%%PK MHTH;(%WHA=[VO`R7(3+E:2&P`V<[T5!F=!4GZQD-\[3WY[>`D[EZ)J96I\]: M%%]%"V@VCLD-8*?4WD&?"K>%A\.;T]M^`-\U*:!DA\;^4*-V`X&HHTP63NF+AJ4`!>B10N&6@(.V=T@H5%8>N,3N^#^4,TC1%.=F#L M5CA*2OC!6"7_>%#B3<=<>.($B0=-GF%4^99(5.=( M5HXEHYA3K&_0V&,>1XLT/*(;_!]F[3%XO6!&1(AJ1DDHXUK2Z_8,E1W8579V M.2EKOW%=9O)ZF>G_E'%@]/M:?'3A]94]I@_0BWYF+PLYBV?1FW,?&G.G^EE? M[(J68R>^HL?$>!M!BWC$>!$^CG[F$G0%GZ!I#.'JX*(6X[#&W?$K6$WZS(PO M,(4=J^`;TY5H#6F@Q*-1\(!-:)]CO["JZQ.U4Q;SUS_6^+L!G$L4(+A4R@X+ M]Z6,/[#\+P```/__`P!02P,$%``&``@````A`-][8A),`@``!04``!D```!X M;"]W;W)K&ULE%39;MLP$'POT'\@^!X=/A)'D!S8 M-=P&:(&BZ/%,4RN)L"@*)'W]?9=D+3MP6J0ODD@-9V=G1\J?CK(E>]!&J*Z@ M:910`AU7I>CJ@O[XOKZ;46(LZTK6J@X*>@)#G^;OW^4'I;>F`;`$&3I3T,;: M/HMCPQN0S$2JAP[?5$I+9G&IZ]CT&ECI#\DV'B7)?2R9Z&A@R/1;.%15"0XK MQ7<2.AM(-+3,HG[3B-ZKOK[[B2/5)L1"OLR9-2(GGV7'=*LTV+ M?1_3">-G;K^XH9>":V5492.DBX/0VYX?X\<8F>9Y*;`#9SO14!5TD6;+"8WG MN??GIX"#N7HFIE&'CUJ4GT4':#:.R0U@H]3609]+MX6'XYO3:S^`KYJ44+%= M:[^IPR<0=6-QVE-LR/65E:<5&(Z&(DTTFCHFKEH4@%,`,B1C6# M))1Q+>EU>\Z5'=A5=G8Y*\3M5$6\^E##^P^6\```#__P,`4$L#!!0`!@`(````(0"+)="U M=@(```8&```8````>&PO=V]R:W-H965T&ULE%3+;MLP$+P7 MZ#\0O$>4Y$=BP7+@-'`;H`&*HH\S3:TDPJ(HD'2<_'V7HJW:<=`Z%TE<#6=V MA[N(.EZ9BMC/`BWZ3:E@:QU.F MN&QI8,C,)1RZ+*6`>RVV"EH72`PTW&'^MI:=/;`I<0F=XF:S[:Z$5AU2K&4C MW4M/2HD2V4/5:L/7#=;]G(RY.'#WBS-Z)8715I<9F#)D6\T)B M!=YV8J#,Z3+)[J:4+>:]/[\D[.S1-[&UWGTVLO@J6T"S\9C\`:RUWGCH0^%# MN)F=[5[U!_#-D`)*OFW<=[W[`K*J'9[V!`OR=67%RSU8@88B391./)/0#2:` M3Z*D[PPTA#_W[YTL7)W3-(Z2<3Q%-%F#=2OI&2D16^NT^ATPR9XI<*1[#GSO M.4;3:'(=CY+_D["03U_>/7=\,3=Z1[!E4-)VW#=@DB'QV_5@(1Z[]."<8DMC MKA;/X&DQGG%-\#LE?QP-M$`Z0<=\LQ^6,WZ/CP6CXPXQ4\0(```8&```8````>&PO=V]R:W-H965T&UL ME%1=;YLP%'V?M/]@^;T8"$U6%%(EJ[I5VJ1IVL>S8RY@!6-D.TW[[W>-$YHT MTY:^`+XWSZIECR"L5)W!4VBF!+HA"YE5Q?TYX_[JP^46,>[DK>Z M@X(^@Z6WB_?OYCMM-K8!<`09.EO0QKD^9\R*!A2WD>ZAPS^5-HH[7)J:V=X` M+X=-JF5I'$^9XK*C@2$WEW#HJI("[K38*NA<(#'0V!3XA(ZQ!E!(E\H>ZTX:O6_3]E&1<'+B'Q1F]DL)HJRL7(1T+0L\] MW[`;ADR+>2G1@2\[,5`5=)GDJREEB_E0GU\2=O;HF]A&[SX967Z1'6"Q\9C\ M`:RUWGCH0^E#N)F=[;X?#N";(254?-NZ[WKW&63=.#SM:S3D?>7E\QU8@05% MFBB]]DQ"MR@`GT1)WQE8$/XTO'>R=$U!TR1*LGB*:+(&Z^ZE9Z1$;*W3ZG?` M)'NFP)'N.?"]YYA,H^M9/$G^3\*"GL'>'7=\,3=Z1[!E,*7MN6_`)$?BO_M! M(QZ[].""8DNC5HMG\+B8I7/VB'43>\@J0/`Y0I(1P3#GF!B379[8@WUB7UBO M9!4"QVE>A)RDF;PEC0<7%)^C^%D\J@^)`R0;FN783O:6/!Z,!3^6?U;(/>9$ MS&04<^(16^CR4GKPD'NL98B<6YJ>TOJ63S.EJMDK(V'N M0F,J,#5\A+:U1.BMGZD46VV,CN.^3/TAO(YG^7*X!MCX`\>PYS5\Y::6G24M M5$@91S.T;<(@AX73/>K&:=0.)W#X;/"^!6RW.$)PI;4[+#`Q&V_PQ1\```#_ M_P,`4$L#!!0`!@`(````(0`X.E8X3`(```4%```9````>&PO=V]R:W-H965T M'3Z26K`4V#7:/QYE2_:@C5!=3M,HH00ZKDK1U3G] M]7-]]XD28UE7LE9UD-,3&/I8?/PP/RB]-0V`)@&0F4CUT M^*926C*+2UW'IM?`2G](MO$H2>YCR41'`T.FW\.AJDIP6"F^D]#90**A91;U MFT;TYLPF^7OH)-/;77_'E>R18B-:84^>E!+)LZ>Z4YIM6NS[F$X8/W/[Q0V] M%%PKHRH;(5TO(.K&XK2G MV)#K*RM/*S`<#46::#1U3%RU*`"O1`J7##2$'7,ZPL*BM$U.Q_?1]"$9IP@G M&S!V+1PE)7QGK))_`BCUH@*7E[9BEA5SK0X$QXUHTS,7GC1#XK.FP#"H?$LD MJG,D"\>24\PIUC=H[+Y(D\D\WJ,;_!]F&3!XO6`&1(QJ!DDHXUK2Z_:<*SNP MJ^SL.ZS.CU,N/_*>/`Z/>U^.3"&RH'C`_0BWXF+PMYBY,WYWYNS)WR ML[[8E4R'3D+%@$GQ-H`>9@,FB`AQ##.7H&OX#&UK"%<[%[44AS7L#E_!8N0S M,[S`%/:LAF>F:]$9TD*%1Y/H`9O0(<=A857O$[51%O/G'QO\W0#.)8D07"EE MSPOWI0P_L.(O````__\#`%!+`P04``8`"````"$`,)]CKIX#``#]#```&``` M`'AL+W=O+(-LONWW?&#B%.PB:\[F>M(1;*8)#RC*_>=2O=^_?G3\L3%BSQ0JAQ` MR.3*/2B5+SQ/1@>:$CG@.P]F0M*8KTH3;S0]R=>2ECF&H2% MZ(/!=SL6T4<>'5.:*0,B:$(4[%\>6"[/:&G4!RXEXN68WT4\S0%BRQ*FWC6H MZZ31XGF?<4&V">A^"T8D.F/K+PWXE$6"2[Y3`X#SS$:;FN?>W`.D]3)FH`#+ M[@BZ6[F;8/$0#EUOO=0%^LOH258^._+`3U\%B[^SC$*UH4_8@2WG+YCZ'&,( M%GN-U4^Z`S^%$],=.2;J%S]]HVQ_4-#N,2A"88OX_9'*""H*,(-PC$@13V`# M\.JD#$<#*D+>]/N)Q>JP>7",,-> M)53_=3T=+[U7*%A4I#R8%'@M4X(RPP/.DAC(^A-C,A)C17$G#R90I0G;:8:W MT&#RRH77D*F=T"P\F0\&KVV\4LLBQ-G,IME5*Z'[_4F*R MYBYK:2)-21,;%F=]Y,\'D/[QE.`ZF\%$0-&EKI.RKI84.`W]I6"R360B32GH MO[VG')-M6!.Q]C]MW__\%B),MHE,I+G_`)RJ*D#[S@R"'W="+[,9SB%+S*Q= M#`YHE;6##+-K9";4HJ=V^K4>OW.R@N+8&U_41G`.67KF5_3@X:V,`;*&XVY6 M<^:A&N61"8I0E75VL0IKI`-(JK..>FC%9;5R%B&+]8J]XE.ISAKBO MJC$4)F)UY\IC+ZR92(>X?.9D3W\0L6>9=!*Z M`TQ_,(4S+&PO=V]R:W-H M965T&ULE%5=;YLP%'V?M/^`_%X,Y*M!(56ZJENE59JF?3P[ MQH`5C)'M-.V_WS5.&"Y5FKX`OAR?<\_UY;*Z>19U\,24YK+)4!Q&*&`-E3EO MR@S]_G5_=8T";4B3DUHV+$,O3*.;]>=/JX-4.UTQ9@)@:'2&*F/:%&--*R:( M#F7+&GA32"6(@:4JL6X5(WFW2=0XB:(Y%H0WR#&DZA(.612N*M_K$)N@E=(*HW;Z]HE*T0+'E-3Z!8D:%-G-[&$<+K55>@/YP= M].`YT)4\?%4\_\X;!M6&<[(GL)5R9Z$/N0W!9CS:?=^=P`\5Y*P@^]K\E(=O MC)>5@>.>@2-K+,U?[IBF4%&@"9.99:*RA@3@&@AN6P,J0IZ[^X'GILK0)`ZO M9[/I_'H!-%NFS3VWG"B@>VVD^.M0\9'+L21'%KB?6.;A;!%-8A!]AP2[C#J# M=\20]4K)0P!=`Y*Z);8'XQ2(WW8$5BQV8\$9@JZ&7#46$[ZLGI.%K[D>24+]I5<9.S$SN%!D[O/]UTG=I?/[R*> MD>G;1I:^XGDC%NP+N1YF;WRXN:A&Q>"J9)]876M M`RKW=M8E,`#Z:#^'-XG]-%['I^G&S6?BK=IUT#H725P-9W:'NYS?/:N&[,!8J=N<)E%,";1"%[*M+"WHEA=%6ERY" M.A82O:QYQF8,F1;S0F(%WG9BH,SI,LGNIY0MYKT_/R7L[?S*R^"); M0+/QF/P!K+7>>.ACX4.XF5WL7O4'\-60`DJ^;=PWO?\,LJH=GO8$"_)U9<7+ M`UB!AB)-E$X\D]`-)H!/HJ3O##2$/_?OO2Q(IHL@;K5M(S4B*V MUFGU*V"2`U/@2`\<^#YPC*;1Y#8>)?\G82&?OKP'[OAB;O2>8,N@I.VX;\`D M0^+7Z\%"/';IP3G%EL9<+9[!;C&;S=D.?1,'R'V`X'.`)`."H>8@C&+7"WNP M%_;&^DSN0^!4)GU=9O06&0_.*3Z'Y&_C@38(!\BX;Y;3P=4D_F-K MJ"0,7NA,!::"C]`TE@B]]4.58J\-T6'>EZD_A;_CXVS9WP-L^(%SV/$*GKBI M9&M)`R52QM$MEF+")(>%TQTFCN.H'8Y@_UGCA0O8;W&$X%)K=UR@,!NN\,5O M````__\#`%!+`P04``8`"````"$`D[O8HG8"``#B!0``&0```'AL+W=O'5(U&\7QE"DN&QH84G,-ARX**6"MQ4Y!XP*) M@9H[U&\KV=H3FQ+7T"ENGG;MC="J18JMK*4[=J24*)$^EHTV?%NC[T,RX>+$ MW2TNZ)441EM=N`CI6!!ZZ7G.Y@R9EHM=!?PU9`<"KZKW3>]_P2R MK!S>]BT:\K[2_+@&*S!0I(E&MYY)Z!H%X),HZ3L#`^&'C(ZPL,Q=E='Q-+J= MQ>,$X60+UFVDIZ1$[*S3ZE<`)9VHP-5)6W/'EPNC]P2O&]&VY;YYDA2)3YH" M0Z_R3R)1G2=9>9:,8I]B?8O!/B_GTP5[QC#$"^0A0/#90Y(>P5!,KPA5#!6] MG-A0.D$D7]M#.Y+R.#WB, MK?-W6_X0WLC0QD6@+YBAJ/FL%W46*;;']9%Z<%>[SS3L7%J;GM-Z:]-_6O.' MSNG##MKI.V-^]\I'F*G0N`I,"1^@KBT1>N?G980=U^_VH[P:^;MXO3])5]V( ML_X#CEC+2_C"32D;2VHHD#*.9NC:A"$-"Z=;U(V#IAT.5_=:X;\4L.OB",&% MUNZTP,*L_SLO?P,``/__`P!02P,$%``&``@````A`/S^5DJ_`@``?`<``!@` M``!X;"]W;W)K_E*VB0H MI$I7=:NT2=.TCV?'&+"*,;*=IOWO=X<3!J7+NA<$Q_GW<7<31G:U@B6=X=4'291=!4J)AOJ$5+S%@Q= M%)*+6\WW2C3.@QA1,P?Z;25;>T)3_"UPBIF'?7O!M6H!8B=KZ9X[4$H43^_+ M1ANVJ\'W4SQG_(3=/4S@E>1&6UVX`.!"+W3J>16N0D#:K',)#K#LQ(@BH]LX MO8DC&F[678%^2G&P@WMB*WWX:&3^638"J@U]P@[LM'[`U/L<0W`XG)R^ZSKP MU9!<%&Q?NV_Z\$G(LG+0[DMPA,;2_/E66`X5!9@@N40DKFL0`%>B)(X&5(0] M930!8IF[*J.SJ^!R$KTZ)V),1F*L%BJY\8$A3?(ZS>Q_:#`9RCT0OXAZ6$_L M4^9=L8=VYF,>+/`,1N>\+3P$'1G:F!3TF#,4M5SVHD8EA?%X>TDQN>/N:^HC M4VM78UBT-H]6`:2?=X?GQ@P^`H[ZX5BN7K>R&'.>)\+D,9&/3*W@CGWQ&7 MGZS?=7ZA*&%*\4'4M25<[W&/);`)^FB_8[<)?B,OX_-TZW=OV+^!W=>R4GQA MII2-);4H`#,*%F#&^.WI'YQN03EL0.U@ZW6W%?SE!*R#"(>QT-J='H`Y[/^; MF]\```#__P,`4$L#!!0`!@`(````(0"NZ$1(,@$``$`"```1``@!9&]C4')O M<',O8V]R92YX;6P@H@0!**```0`````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````"&>TOIG)FD98F:G5QBXLR,-X1O&[%0`FBW?R_M MNCJC)X_D?7EXOH]ROM=U\@G.J\94B&0Y2L"(1BJSK=#S:I'.4.(#-Y+7C8$* M'<"C.;N\*(6EHG'PZ!H++BCP22093X6MT"X$2S'V8@>:^RPV3`PWC=,\Q*/; M8LO%.]\"+O+\&FL(7/+`<0=,[4A$`U**$6D_7-T#I,!0@P83/"89P=_=`$[[ M/R_TR5E3JW"P<:9!]YPMQ3$G?M14F6Y7`A#K M]E-S'Y9QE1L%\O;`]F^N3KS?E?AW5DK1VU'A@`>027R/'NU.R7IR=[]:(%;D M9)KFTY1!?Q-/`-9[__QS]@4``/__`P!02P,$ M%``&``@````A`*>?O/>5````J0```!````!X;"]C86QC0VAA:6XN>&UL/(Y! M"@(Q$`3O@G\8YNYF]2`J2184?($^(&1'$T@F2R:(_MYX\=)0-%2WGMXYP8NJ MQ,(&M\.(0.S+'/EI\'Z[;@X(TAS/+A4F@Q\2G.QZI;U+_A)<9.@&%H.AM>6D ME/A`V/$K-KG6L3R5+)3=+(&HYJ=TX[E7N`K3:0S5X/B+$_@$A_5)9 MK?XC]@L``/__`P!02P,$%``&``@````A`+/88C]$`@``+08``!``"`%D;V-0 M&UL(*($`2B@``$````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````G%3?3]LP$'Z?M/\ARCND+0PFY`9!*0-I/ZHUL$?+.)?6(K$SW[5J M]]?OG*B0;N2AO-EWWW?^SO=#7&ZJ,EJ#1^/L.!X>#^((K':YL8MQ_)#='GV. M(R1EE6!I60T&)PEL"&P.>1']4O`N(UXL:;W!LV=#OKP,=O6+#@5 M5W5=&JV(LTR_&>T=NH*BZ49#*9*N4["Z.>B5-[1-!R+I7L5#N`,5/FVFC,=4K.EB#9J:,LL:P`:R_-N:R1 M?/K+^6=<`A"*A`&ML3EVL=VS.4V'YPV"3_O($*%5PHY]C9FA$O!',5.>WI`\ M/.]J;E2TBEM!NRI*[@TYM<3_)>]M6VWCNLI?OX,R?`=G]";GNR.00YDM04Y<52N[[8>-Y!?'E68@"_>V'W@BKQ4:E*Z0 M,P_(+=\T8#_A-,3D823S5((,FE!F3O[D3GOYQ-`S;04:S9_86RJ"7(8R;F7F ME46ER?13SD**E:$P@]B4CU\ESJB?$WRNFR.DZ$/O!/6G+A\,ID\,I MMX=3IH=3WN[6IB)]Z=_O=>O>7/XSB5^-?<:'.G,W7-C=JMDWBOE2>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A``0>IBJ<`@``L`8``!D`````````````````&Q0``'AL+W=O6QE&PO&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`$&;ZSH-!0``=1,``!@`````````````````WT$``'AL+W=O&UL4$L!`BT` M%``&``@````A`-"8?=Y-`@``!04``!D`````````````````ITD``'AL+W=O M&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#@Z5CA,`@``!04``!D````````````` M````"50``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`-H:>"Z\`@``H`<``!@````` M````````````8%H``'AL+W=O`(```<&```9`````````````````%)=``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`).[V*)V`@``X@4` M`!D``````````````````6```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*[H1$@R M`0``0`(``!$`````````````````HV4``&1O8U!R;W!S+V-O&UL4$L! M`BT`%``&``@````A`*>?O/>5````J0```!``````````````````#&@``'AL M+V-A;&-#:&%I;BYX;6Q02P$"+0`4``8`"````"$`L]AB/T0"```M!@``$``` M``````````````#/:```9&]C4')O<',O87!P+GAM;%!+!08`````&P`;`"8' (``!);``````` ` end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 5. Related Party Transactions
 3 Months Ended
Mar. 31, 2015
Notes  
Note 5. Related Party Transactions

Note 5. Related Party Transactions

Fair value of services: An entity controlled by the Company’s sole officer and director provided corporate securities compliance services to the Company valued at $3,500 during the three months ended March 31, 2015. As of March 31, 2015, $4,000 is outstanding in accounts payable.

An entity controlled by the Company's sole officer/director provided corporate securities compliance services to the Company valued at $5,000 during the three-month period ended March 31, 2014, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of cash advances received from our controlling shareholder. Such items due totaled $28,113 at March 31, 2015 and $18,375 at December 31, 2014.

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5?.3DQ85\P,S!D M.3`X,&-B-SDB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,U]"87-I#I7 M;W)K#I7;W)K5]4#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X M.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A2!);F9O'0^06UE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H M87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!6;VQU;G1A'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5?.3DQ M85\P,S!D.3`X,&-B-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8S1E8C,V.&-?-C@V-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C'0O:'1M;#L@8VAA M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF5D.R`Q+#`X."PW-#`@:7-S=65D M(&%N9"!O=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB M97(@,S$L(#(P,30\+W1D/@T*("`@("`@/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5? M.3DQ85\P,S!D.3`X,&-B-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8S1E8C,V.&-?-C@V-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C'0O:'1M;#L@ M8VAA6%B;&4@86YD(&%C8W)U960@97AP96YS97,\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!F:6YA;F-I;F<@86-T:79I=&EE7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/"$M+65G>"TM M/CQP/CQB/DYO=&4@,2X@5&AE($-O;7!A;GD\+V(^/"]P/B`\<#Y!;65R:6-A M;B!":6]G96YE=&EC(%-C:65N8V5S+"!);F,N("AT:&4@)G%U;W0[0V]M<&%N M>29Q=6]T.RP@)B,Q-#<[5V4F(S$T.#L@;W(@)G%U;W0[04)3)G%U;W0[*2!W M87,@:6YC;W)P;W)A=&5D(&EN($1E;&%W87)E(&]N(%-E<'1E;6)E2!B=70@'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6EN9R!F:6YA;F-I86P@2!T;R!C;VYT:6YU92!A2!A9&IU2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5?.3DQ85\P,S!D.3`X,&-B M-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1E8C,V.&-?-C@V M-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6EN9R!U;F%U9&ET960@:6YT97)I;2!F:6YA;F-I86P@2!F;W(@ M82!F86ER('-T871E;65N="!O9B!F:6YA;F-I86P@<&]S:71I;VXL(')E'!E;G-E&EM871E(&-A6EN9R!A M;6]U;G1S(&%P<')O>&EM871E(&9A:7(@=F%L=65S+CPO<#X@/'`@&-L=61E9"!F6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T M=&]M.BXP,#`Q<'0^/&D^26YC;VUE(%1A>&5S.CPO:3X@)B,Q-C`[)B,Q-C`[ M5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&EN8V]M92!T87AE&5S('!A>6%B;&4@;W(@ M"!R871E"!A2!A=F%I;&%B;&4@ M=&%X(&)E;F5F:71S(&YO="!E>'!E8W1E9"!T;R!B92!R96%L:7IE9"X\+W`^ M(#QP/D%30R`W-#`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`X,&-B-SD-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8S1E8C,V.&-?-C@V-%\T,C!E7SDY,6%?,#,P9#DP M.#!C8C'0O:'1M;#L@8VAA3QB3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G M:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`T+B!#;VYV97)T:6)L92!.;W1E M2!B>2!T:&4@2=S('-O;&4@;V9F:6-E2=S('-O;&4@97AE8W5T:79E(&]F9FEC97(O9&ER96-T;W(N M($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@075G=7-T(#(P,3`@8VAA;F=E(&EN M(&-O;G1R;VPL('1H92!C;VYV97)T:6)L92!N;W1E('!A>6%B;&4@=&\@65A3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5? M.3DQ85\P,S!D.3`X,&-B-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8S1E8C,V.&-?-C@V-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C'0O:'1M;#L@ M8VAA2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!V86QU960@870@)#,L-3`P(&1U M6%B;&4N/"]P/B`\<#Y!;B!E;G1I='D@8V]N=')O;&QE M9"!B>2!T:&4@0V]M<&%N>2=S('-O;&4@;V9F:6-E7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/"$M+65G>"TM/CQP('-T M>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T M92`V+B!#;VUM:71M96YT2!H M87,@;F\@;F]N+6-A;F-E;&QA8FQE(&]P97)A=&EN9R!L96%S97,N/"]P/CQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$;6%R M9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q<'0^/&(^3F]T92`W+B!3=6)S M97%U96YT($5V96YT2`Q-"P@,C`Q-2P@=&AE M(&1A=&4@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H4&]L M:6-I97,I/&)R/CPO'1087)T7V,T96(S-CAC7S8X-C1?-#(P95\Y.3%A7S`S,&0Y,#@P8V(W.0T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-&5B,S8X8U\V.#8T7S0R M,&5?.3DQ85\P,S!D.3`X,&-B-SDO5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!C;VYS:61E'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA&EM871E(&-A M6EN9R!A;6]U;G1S(&%P<')O>&EM871E(&9A:7(@=F%L=65S+CPO M<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`H4&]L:6-I97,I/&)R/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5?.3DQ M85\P,S!D.3`X,&-B-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M8S1E8C,V.&-?-C@V-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C'0O:'1M;#L@8VAA M2`H4&]L:6-I97,I/&)R/CPO&5S M+"!0;VQI8WD\+W1D/@T*("`@("`@("`\=&0@8VQA&5S+"9Q=6]T.SPO:3X@=VAI8V@@"!R971U2UF M;W)W87)D"!I M"!L87=S(&EN8VQU9&EN9R!T87@@"!B96YE M9FET2!I;B!T87@@<&]S:71I;VYS+B!4:&ES(&=U:61A;F-E('!R97-C"!B96YE9FET('1O(&)E(')E8V]G;FEZ960N($9I"!P;W-I=&EO;B!I2!T:&4@0V]M<&%N>2!O;B!I=',@=&%X(')E='5R;G,N(%1A>"!Y M96%R2!H87,@;F5T(&]P97)A=&EN9R!L;W-S M97,@;V8@86)O=70@)#0W,"PP-#,L('=H:6-H(&)E9VEN('1O(&5X<&ER92!I M;B`R,#(V+CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C-&5B,S8X8U\V.#8T7S0R,&5?.3DQ85\P,S!D.3`X M,&-B-SD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S1E8C,V.&-? M-C@V-%\T,C!E7SDY,6%?,#,P9#DP.#!C8C&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 14 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 4. Convertible Notes To Related Party
 3 Months Ended
Mar. 31, 2015
Notes  
Note 4. Convertible Notes To Related Party

Note 4. Convertible Notes to Related Party

On October 2, 2009, we issued a convertible promissory note in the amount of $76,000 to our sole officer/director. The note bears interest at the rate of 12% per annum until paid or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by the sole officer/director, who was also the Company's controlling shareholder. On August 13, 2010, the Company's sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company's sole executive officer/director. In connection with the August 2010 change in control, the convertible note payable to sole officer/director together with accrued interest was also verbally assigned to the new controlling shareholder. On December 31, 2013, the note was formally assigned to our control shareholder.

On December 31, 2013, we issued another convertible promissory note in the amount of $255,681 to our controlling shareholder. The note bears interest at the rate of 1% per annum and matures after 1 year of the date of issuance or the note and accrued interest is converted into shares of the Company's common stock at a conversion price of $0.25 per share. The maturity date of this convertible promissory note was extended to December 31, 2015. The note was issued in consideration of cash advances made and for services provided to the Company by its sole officer/director and an entity controlled by our sole officer/director, who was also the Company's previous controlling shareholder.

In accordance with Accounting Standard Codification (“ASC # 815”), Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder’s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
American Biogenetic Sciences, Inc. - Balance Sheets (USD $)
Mar. 31, 2015
Dec. 31, 2014
Balance Sheets    
Cash $ 0us-gaap_Cash $ 0us-gaap_Cash
Total current assets 0us-gaap_AssetsCurrent 0us-gaap_AssetsCurrent
Total Assets 0us-gaap_Assets 0us-gaap_Assets
Accounts payable - trade 10,800us-gaap_AccountsPayableTradeCurrent 12,800us-gaap_AccountsPayableTradeCurrent
Accrued interest expenses 53,149fil_AccruedInterestExpenses 50,310fil_AccruedInterestExpenses
Convertible note, related party 331,681fil_ConvertibleNoteRelatedParty 331,681fil_ConvertibleNoteRelatedParty
Advances from and accruals due to related party 28,113fil_AdvancesFromAndAccrualsDueToRelatedParty 18,375fil_AdvancesFromAndAccrualsDueToRelatedParty
Total current liabilities 423,743us-gaap_LiabilitiesCurrent 413,166us-gaap_LiabilitiesCurrent
Total liabilities 423,743us-gaap_Liabilities 413,166us-gaap_Liabilities
Preferred stock    [1]    [1]
Common stock 109us-gaap_CommonStockValue [2] 109us-gaap_CommonStockValue [2]
Additional paid in capital 46,191us-gaap_AdditionalPaidInCapital 46,191us-gaap_AdditionalPaidInCapital
Accumulated deficit (470,043)us-gaap_RetainedEarningsAccumulatedDeficit (459,466)us-gaap_RetainedEarningsAccumulatedDeficit
Total Stockholders' Deficiency (423,743)us-gaap_StockholdersEquity (413,166)us-gaap_StockholdersEquity
Total Liabilities and Stockholders' Deficiency $ 0us-gaap_LiabilitiesAndStockholdersEquity $ 0us-gaap_LiabilitiesAndStockholdersEquity
[1] $0.0001 par value; 10,000,000 shares authorized; none issued
[2] $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at March 31, 2015 and December 31, 2014
XML 16 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 2. Going Concern
 3 Months Ended
Mar. 31, 2015
Notes  
Note 2. Going Concern

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management's success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubts about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.
XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 18 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation
 3 Months Ended
Mar. 31, 2015
Notes  
Note 3. Basis of Presentation

Note 3. Basis of Presentation

In the opinion of management, the accompanying unaudited interim financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. The accounting policies are described in the “Notes to the Financial Statements” in the 2014 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (US GAAP). The results of operations for the three months ended March 31, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates:   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents:   For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments:   ASC # 825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share:   Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2015 or 2014.

Income Taxes:   The Company accounts for income taxes in accordance with ASC # 740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed “more-likely-than-not” to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2015 and 2014. The Company has net operating losses of about $470,043, which begin to expire in 2026.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

XML 19 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
American Biogenetic Sciences, Inc. - Statements of Operations (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Statements of Operations    
Revenue $ 0us-gaap_Revenues $ 0us-gaap_Revenues
General and administrative 7,738us-gaap_GeneralAndAdministrativeExpense 7,500us-gaap_GeneralAndAdministrativeExpense
Interest expenses 2,839us-gaap_InterestExpense 2,824us-gaap_InterestExpense
Total costs and expenses 10,577us-gaap_CostsAndExpenses 10,324us-gaap_CostsAndExpenses
Net loss $ (10,577)us-gaap_NetIncomeLoss $ (10,324)us-gaap_NetIncomeLoss
Basic and diluted net loss $ (0.01)us-gaap_EarningsPerShareBasicAndDiluted $ (0.01)us-gaap_EarningsPerShareBasicAndDiluted
Basic and diluted 1,088,740us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 1,088,740us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
ZIP 20 0001295345-15-000125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001295345-15-000125-xbrl.zip M4$L#!!0````(`&-[KD:1L8)R(A@``-U[```1`!P`;6%B82TR,#$U,#,S,2YX M;6Q55`D``PKW5%4*]U15=7@+``$$)0X```0Y`0``[3UI<^,VEI\S5?L?,)5, MG%3IHB3?[IYR^\BX.FT[[>[)I+:V4A`)24A3A,+#MO;7[WL/``E2U.4CSNSX M2[!C$9OMF2BFGM[V_M-;^OO M;__K+T=_;3;9=:R"S!D/QQ^33*:")6J8WO%8--AQ<,LCO.%$3:99 M*F)V$47JEJ>`(6G`![_5@&O362Q'XY1]=_(]ZW8Z>\UNQ]MF_WU]_:\/>^^] M_?=>K]>__/!S]WWO^G]:[.[NKB6"$8\)6\M7$]9L(DGW@SADP$.4O-D:I^GT MH-W&>_'KEHI';0#=:\LH29&F+7WG098T1YQ/\Q5#G@SH;G.AC;0T.UZSY]DE M"#"0^0H7_DY;7[2W!J)R7R+\UDC=MN$"0NZ7(0]EF-\^X0..S!$!G9Z#/I31 MEQ*'=SW"[^WO[[?I:LY<&B\4Q7X;KMH;YT"6A8:7!SS)A0;*T.]ZN\O$K._( M:4YD'<5PJ]?^UX_&L1B^V4+Y-JUL6_=)L,7:!,=L_,$)3\8L$+Z<\!`TZN+R?(OY M*DK%??H1`9QYVS_!IF21U)\_WYQNO>T#SQ&P-=36X9I.^K+$J3:S[C@U!\BGD@'BIYK[/7<;$M!OTT M),RQZG4W(@"<$MX39R*X`+BQ2-*S^ZF($K'YQFWWO/[^47L)R,>AG.,5K-OK MK(?P1$40_%(),KA4J?@H0IZ*X)K'Z6QC/L&E[.QY&N\2N(_'/KO;#R#)6LJ/D@]D*%,I M'NQV^]W>;K]7&-\\R$=AG&.Y[X$^[#P$WU.R]C`E4/7OM.3E*!^RB*^JOIF;?HM:DY#@*)909:ON/M>T[PK`?[>-3SRK\YXH\BY3(2P1F/(RCB$O!RV20CYW8JAM*7F_NO M9G^WTW&M?#6.)R5I3BS-_O9^WW4*&Q)$ZC)680!U[]GO4%%N'NF:5<\W#_-1 M*&MXKCC"%0@=/PFQ[@DX[M3ZX%K83TC(LIQ](S(^BEL19STG>%2@/1Q3#8_=O6Y_/4PG*DE1@=>I=FJ9\CK;N[MN2"S#>P2R M&KZ\3L]E;"FR2Y%>1+Z:B!]5LCE;S0I?)6@/Q5/#4;/"TF(\-KQ*18\$2<"OW_151IX=F&AGA0'-$D4G!\(+;GH[16F+EN M/914Q]MCE[W8@,\)]@NOI@*SD&AT[$,NLK)Q41_`]DL9U_J8GH7`Y1GHTQ)W M$=U"LO,XZ:TFK@;+LQ#W(,DM(@YU%N[U?1%0(])M/+Y3<:SN,,YN;KM:U]:# M_F2$U)EF9R,J5DCQ7$8\\A^G2&M980VB9Z'O0;JTBCA<`VX._\/*]Y:'`OV? MB*4*JO[Q,7:X"9YG(G"Y_#8FD$Y,X.YW8B0CS'"OAOKN];L2):VOA?483+V' M8SJ+@O5P+,FB*G`>!G^)EZB#GQL#3^'6JZ&)02I*:I3U[;=A>OC79E.,[IO- M;T?I(7Z>VC\&^`<>@S&OQ3Z-!U>;[F?YRN,)$./SB+V3:B0B MD4J?W?A2X-F1'F!AWZ4`[%L^F1[^GJGTT(+-OVCHBU][_=W#GX7]>^^0J=A9 M=OSNIOCP/;OC"9-0><93%:._A`_L%%PGSM4P%;$;,4T%U@3,:S!O?Z_78M<@ MM9BEBOF@TJ`(3*8)4X7``$*WT^DV6%HP3WA$-((2@U#@)2A(!(_]<0-V\E:$ M:CK!8R>H-]B4YGT0&E-#-I"J.85Z9,)]D8%<>&AO2%KLJD3B?L-!_1$T%?LZ M`!2V'?`.@>P!C[[$V33U9Z`=`:S!.S^W;EKL77'E1`7"4CE_+8M3=L:35,0@ M*L0@_13IO!1W[!<5?R&B+M6MIJE/)&V7I2%@MU$20PA4<\!I_7$VRI*4>3U< M[G5*R^W6[APF+%$A[--P"`E]W`YD+/P4-P>X3O3Q#PF4)XD<1?!A++5"QRID M"38OV50EU-_'#07URZ)8!TY`*&/8"CK^'&0I;->$^MT`;"DQXE[X&?;2YLAJ ML4+SG?@S9W+E)G8VP"(TE3P\5=D@/1ZH+/U!@=Z=*#"../H$QODN1%;6M53@ M?!:*-]]RX/UPPF-P:`<=&9D_FP.5IFIRT(+:R9NF^JYYX^ZV&%'!#!ELN7VC M(^!0))#,<-E0QU>.^P#R1MU/V)B#V`9"1*#A`D1/TDZR"2XH69,,0V)71IG` M#>%L1,3XFIB2XP&H9.,9J4,(13&Z%/PR$B.N=\K*'LCQ<7IH&*J[A%2'[E.P M^[I;K"$/,]PS5'J7*HEY")0[`=IQ-@6=^L`CL'CD38L15"2##"TA)X%N0PS! M*%.-*903B8H'?@',`.Y"E9QF<8(LPG6X%]0(6!UDX'80"(AS`&)$PHDN".0@ M`'U>E;"82_@B*?2'!:A`@`Q5J*S#FCC=VI^1;ULA7(!/!;V#*^G(ZYBF;T!`BCY$\\@`IFF6&P/%(*9VUZNQD?4,HV0]V;I*KH2E0 M#1M_G)GTT'D"!:@KU^CQHY3V:[FU7&C?JZ8R,D%@DFN2=H4E6\HBG@521R]P MRW)2OS?YIH#Q.)O20(D`B20<0*6B<`:;"/$F!%U$L\$+W$QN-,!J4(-Y/*.` MPMF0R[A`@Q`*[-:[-E"KLS`E.12QLD&*75B65#LPF:(,>?,O#( M(@82/PJ(V2D&Z7.XG7F=YD\L&:LL#,"%`#Y.BX"WWT"U"-B=3,Y#J;!ACR&HQ\ MHMG=1B[R7+R:;N2L"9Q!+A'B;`\(78B4`0B.;AM5W"0;)$=]L(2.#)0!J,=, M"!(/^,[$?ZN[=9O2H-`;*)&4W0IH<"`3'YPY^&%P=0(JCU@/2+MB!?;]@/Q\?7WVNV:Q4XW^YT'`O!)N!: MQHG9]@^8W-D]WZ:M11ZL@"70(L%9^R8$#8W)F^9/CL]B&&;`-&D5?$&6![Y5 MP968?#Q(`*W/.H`IY?:MVE2[$-"UT;NZV_`/B7]`/8S4G8&#F*",#NANJ>_6 M^K;3.2S^0F'I\,UM"KO`':%QHJECS"';K-FE^NTT&YXX?A'-8L*_0`)F";6I M7S:9ZLVBZ,-U&(W)%A#!A#J72";7`ZTZ&!?#4_BYT#:\44?'$>7K"];H`(MV M9;>V1@BYSZFCQJ8<.OCG;=LLMMF07D22T;O-COTT(Z^M5<-]LHQ92`LQ%0+E`N" M"D4J=&SXORCX>W))XG$%T]-<0%'AZ2\BJ+>RR3HR/;XY85^SO2Z47CG8HO(] M=;RGS@?70-DHUCO(I"0T6'K*G6F$U@(GBE5<+0\P76,*GKZU1/H0V)]XYTYUX6-IH-=%M')KG;> MA)56PVX7A[RN;[4>U9XUEQ"[$!Z,7T>54+<*"E^R"5VXTD";!V"2>IVOF/A' M]:0_YDF^3C=!OJ.<7PZ-#[7W(WOB7L2^3`J-1J^,QZ?@#R%EUQFSX5$+A"[G M:8LF^'M::RB3H/$$C\P7;_)I@#XQV0)>-XT;5PI3.]&KB0899,+FPG9[*#70 MH;112'>AC,@`Q;U)[O,(J?6J,T<=5D,29$@ MDU.)A28A4HMIS'-;'8)X$.B_$>J`C&).UVI4"+U+C$DW;J!E:)V%=0X10R#5 M,4_M'?0,$/O$[]=+,VT2D/M>%+?40%($@LX/+\8!52H4]G5@W.UW:@.CDQTC M,)>B^O!W-Y8@FCP(0L6L1I&TNF/#6%`FR\8(P`!:G46!_A0Y=\$%<-I.B>&; M'R90#8#&82\4.$Q?"E?;;E&:0BT)RFQ"'216V.F&XEVGA=1@-U4XA(0FP+SC M<0"!ZH/@&,IM31]8XW,H!->GXS`J;L1]:IO"]R&_LW&1=`^9P5#>*"KPR6KH M)K,>"%T-Y;^`=4(WW#6`DF&(K32LK3#,:BJ4Z0&$\G_%@C((U`"4`&K)!*PO MA()LB`E@6J[,4<9.9XJ*1L!J^QK4L0`QC"#!)`U#^Z;J'=MFZ9UJ)JF88K_> M-UED(#`H0T*B,5'XI:RSX"6GGC0)Z8=T+$Y,Y\=%SR;8)(=[!89K;C@OHPCE M%Q'*L5*!KG\`/K5/!]@;3/0,M_;$XAY[^I!7B'L^R?N*%\-YM-3I%)BU%+V) MB8I%DY#-FH`H:L*&..T(S5..L8872<*/:-\IW5LB+4=2N9AL05]7;)J.2R%M M=)X6!O4D^:PL#3%Q`-:+];^RC=1':<10L]%7F(Q.T*@)CP M$,:<86"3@[6BY3&0M]D-?=>?HH!P3J(S/@$>2%J9=)>0K'0P$8 M/3$K8LV"@Q4GBXC$7;ECHB*%*N5TW\<<\#`\#P.'Y^/IH#3T1(O.M>:;4J5Z MW6II_?G67`.^U)X_%8.TJ$5?Z"P+-,?Y"2?+NZQFAH;1$,WRCOU5Q*[\5&&* MWZ43SWW0*I'OJ\EP-7S8E0E<4/&,VLO6;Q7>Z9O=G090C"1@M[GVC%,K.ZT? MD+E+,^YN6T^Q:3UYW;]1TLHC*$$8;@'L&)=Q6N!Z=X@-7;R-)R:+MS\GA0< M=B#R+"@Q(YTH6IKBL0FR=0;&<=9*$LU?$7)*!6HYHQ/CD.P2B=8_>5GCH-H< M^KW\(;5#R+(#Z@N2>R0JYR6&26200?D8C839(:2QX91P6L%I-VV*BVI3S[\: M"6I?$YHY[H5,WJ`H8#2X7O@-P@='7 MX'#,/M+]^R+.8GN=M5'F"[MS&FJ%\AK94M#-Y#41L8C5#=K^P]S/IBXU%L!"17+IQ19 MLYNM*YV%SG^URX(ZY%:J;(GO6G#N/%,56+Q`<6=`GB1[<"1 MMI1*D[NQ]F-4?`AC7;]GD/@/9S0_`=L+:D>-FZ#@WNW>8EUF3*[%;C)(1I^( M*2CS`W/L6+20](;H*.$0M*`I7Y?4+4C;*C_2+":0/V&LX[I\>/%T#\R^E-DQ ME[KE:1[^(2;Y".:'F`#RB=*4F6Y7V@:;NY) M2'W[91WA+$N?GE(HV\1)52A-$HIIW=:)IF\K1_3$6*_&@3:JZK$/;:?$>X:A M;E`9!U,:FW'&"G@^L:`#1.E'NL5ITM)S>VR/NWH.8CEPBLEC<_(3Z"ZZS2BG MYK=6SO%!.?9AS5H,;RS-4,B126#08DDY[O(WW;V&Y_465/+?>'N-WNXV7JT9 MG*ES1ALXFKD'9TA]((P#[/9,'P?99[*HIBDX_:$.H^K--BP2G_I'9^;S-IS\W` MZD[6V2VN?Z$]V46-SGMJFI354Z_YS'.>Q6`R6%'\V@$92BX+A.)63T3!'JIL M-`80,^;UK3?.L_>%\VW4(W+.UM)2YV@.D>X64:O8C,P@Y#7H7CB]6;N%I8W^ MG(BK83YHM/%/#U['E?Y#QI4*O2IKS#H_@,*1M]D?ZD%>9Z/F@\$Z>U/:3><' MW/ELDE,_ZJ5_V&Z^SF>]SF?]R>:S"N-:RU26/M'DI9SDZW38ZW38ZW38_[_I ML,4/-5H6\O7LU2=^_U+NZ'4<[74<[74<[74<[74<[74<[<\XCN8^Z[(^5%:> MIW-7A)/KTFB87O9BL^>5H946YF"/X5*`E\]#7OOC^B&$-*$AE>[-(9S1 M.6#QN))+/JFE:]DS8N@1,1I)';@*KA,@(<:B.!#W[T5MVPB4M;.WO;._UW>A M5A;F8,TS_L]EXO/P%_!W2\3;;'K=7+:+%E8)+AZYKA]E>>46@.L_:&CN.9CK MH:A0L`JZ`YEZ&(3T`8(YSHJ9'D#8YO M06C:VZ\$M0JF+5TL_7XX_`L]ISAU]$4A)6[<(*]'^J$(PM8"/8GKPZHLXC`FH7T?@.S$+[^ZDC/$=#?7QU)?/H*YLY0B.,[JD3I MO5;VM6`G%^_+)EXLTS#;#M"C:?Z@+/@`-A&G9*+VC67XT-[B6WV7,&;L^E)1 MF#8@*(`>M0UG^`K[W2;TO]0N.?3G\G\(_?V7 MIKYOH\7FU.LG][VXC?37L)'^8VRD]])[U'OX'IV]V!Z5+7P3"\&`3L130*=[ M3?_DK7D=X0%<.6K;+PD`+BJOMKE("8#N,:Y<6WIN.@$()$Z#&=[PODN())"D M*RV(-6C\RF"J+"1@IR)25)O.@ZNAV$*JKH(@EU-9QY5^3&-)'E/X9Y$TZ"6+ M0Z52'$G]$3Z4WL5H!Y_MVQAC%8HE[WC$R_3^24,`K8'RHP03/B,S%F3(!R)< MYW5/<&/YI9!?K_>*J/83T]+?F)+^(^E8\$:HQ60L>874DU*Q3!0+7QKE4F`5 M[S@N4\)C?XOA)&1LWFVK+^+QR8:JDJHW6Q;+K]O;_9.SLY-.#A#PK%!IS`8?,Z^!8,XTVFZ,[GJ5C%6,3\Q"'..TXX%&[ MQ,=3L=9]3M:6\N8U.GM[#3Q.67!:7-^UG9LWKA%,Y2L,N_#U$;UU&O[X/U!+ M`P04````"`!C>ZY&>@J$`L``00E#@``!#D!``#56&UOVCP4_=Q)^P\> M^Y!-:@@AJU10>29&NZEJ.R&Z-VEZ-)GX`M8<.[.=`O]^=B!=H$E*MU;`E]+8 MQ[[GGG.3Z^3D[2QBZ`:DHH)W'+_>'Q^U7-]Y^]_S9R]UZC9:!R[S89_A+[W^]^NCB_\UH4?!&\^7GUM7@3] M_^MH.IW6@8RQ3*/50Q$AU[64&.4_V_;/$"M`)AFN.K6)UG';\^RBV5"RNI!C MS\0(O`Q8>_[LX"`%MV>*KBR8!AG<][Y=75Z'$XBP2[G2-JO%0D7;*AV_%&&: MUP8A42G"7KD9S+5#KM]T`[\^4R1'=$39;9@(#[$5P;.B-8+`S^'L3@^4X,Z2 MI0A^J]7RTMD\VFQ']"T\O_N1MYA<0],*.K?"&C,/%FY*P6``(V1_/P_.RY/V M+,*C1/[H1B!IB/D[*L;`0=/P.J2FCD&9`$2!;=)O/(N5HB M2R9,A/GH#K.5*Z233]W)6SK":IC:E"AWC'&<,O&`:96-I"*Y#7]9JB^7PS^Z M2IG@VEA-2HBE4WE:.>^Z8)%F7K1U)$=]3)@HDU>BA1)I*([2Z8.4A(`G+YU)Z"?9PN+K:D[H)] M+Y$2N*[T/\/LKMYKN10+WZP2?GOYK#FP;V5T2?&0,JHIW%-+!PWH*JD+LM>66.?_%H^A>I%Z=[]=[0[W*2LL),G2;P20S`J`:DCZ6>%VF_ MZ=(],&-C%8K="9[(G9[@YEU.4W,_?A0:[C&D"KW['E3F6BS[FQWI<-=:A#\G M@AE2ZNR7>:-==Z<"N"7*`]"82G,*(A+6MT&RS<=JV5 MVY'O=YLHL-L'JRXA=$&MCZGI)#T<4VUY%I]02M#[X59IKD_5+A_I!55$D>!I MBE\P2Z#L974=MA^FW,WNJ=KCX[C1-WN!:3[D7D.*D/OA26&.#VF?)U[1IR[[ M;=9;^3AK1GX#4$L#!!0````(`&-[KD8JLGBQYP,```H>```5`!P`;6%B82TR M,#$U,#,S,5]D968N>&UL550)``,*]U15"O=4575X"P`!!"4.```$.0$``,U9 M76_:2!1]3J7^!V_V(5LIQAC*-J"D%4E)A9(T"-+=2JM5-=C7>+3C&3HSYN/? M[QTGL*248/`'^P+Q^/J>,^>,[YT)YQ]F$;,F(!45_.+$K51/+.">\"D?79Q0 M)>RSLT;3=D\^O'_]ZOP7V[9Z4OBQ![XUG%N=CY_:?153#982@9X2":=6VY\0 M;@*N1#2.-4BKR[F8$(T(ZA0OO,HIWAO/)1V%VOKMZHU5JU;/[%K5;5A_]7I? M[\YNW.:-6Z^__7SW9^VFWON[8DVGTPKX(R(3M(HG(LNV#25&^3\M\S$D"BR< M#%<7QZ'6XY;CF(=F0\DJ0HX:6`M#9&F"M[$6:;(=NMV76W,E/^"M&`LB5, M1(;$B.`8T:KUNKL29S+M*,':(T\BN,UFTTGNKD9C.E\OPU>S-YS'FS]$TQ?H M+(5%,X\>W232DX)!'P+KZ<\O_>XZ'N7:\6GD/,4XA+%C*R';TO,Q7!PK&HT9 M+,9""<%&'@OB1OV&T?U7D\W)S"E$(M*+AV#C*'#SDN7(\6?9LW->YK)]"$C, M=(Z,UW/GRE=$A.8I\%KJ'-@FB>P(HB'(/*D^R[O"YWN*9ZWN6!D%%2\;93-P#V(GG",77N%?JX3BBG9O06+Y^!PDP# M]\%?P!K^N4TOFX+M""3U"+^D8@0<-/4&'L6^"@K;WR5AIN(-0@"M]M5Q!X1B MU=R/2-Z:#C318,Q4]\$]5L7'W48AXFZ`.J#*VQD5*?<54>$U$]/BU?X/Z7\B M]D\)[5-PJ?*84+&$ST*#^Q""V3L3/M^[RFY,6'!I38.;6:#:)X''DRN!CLC] M&]$+*YCT42-U01[%86 M;`NQL$,DQ]ZD>B!-TQ)\$!()93F7"OW0ANU*LA"?\#@O(G@@L_+ZTV;(0SN2 MBEDQ-D1CW!O?!WWP<(C-NTK%X+<]3\3)'F^@"?>)]%4)]NQ,Y>"V[<7X//D= MZY&EKAG0P(0```^O@``%0`<`&UA8F$M,C`Q M-3`S,S%?;&%B+GAM;%54"0`#"O=450KW5%5U>`L``00E#@``!#D!``#576US MVS82_MS.]#_@TIES.Q-)49STDES2CFS+/4]<6V,Y?9F;FPY$0C9;BE`!TB]S M<__]`)"4*+X`(`'1R)?$EH#=Q>YC8+&[`-[_\+`*P1TB-,#1AX/Q\,4!0)&' M_2"Z^7`04#QX\^;UV\'XX(?OO_KR_=\&`S`CV$\\Y(/%(YB>_#BYHDD0(T#Q M,KZ'!#T'$_\.1KS!,5ZMDQ@1OAB_!O^>S7[]ZZ6%!PB$F-R/&XW"4-WSV MU9=??"$:OWN@P4Z'^\.\^7CTZT_G<^\6K>`@B&C,1Y5VI,$[*CX_QYX8EP9+ MT-B"_S;(FPWX1X/QR\'A>/A`_8*@RR#1*&'&EO3@\'!?:<4HM55#I MDBEA_/;MVY'XMMB:D?/C3?,B]=>C],M2ZT`BSD:QS)A?O",M/5V>-DKW=H95V&O4EXPR1`/O3J)NPI=X]2SV/(8D-Y"[T[TWR:S;_H4XR M%WKV)RV.8=A-VFW/5-IT]N0?G+.?=H1&#S&*?.3G8G,ZDK]CP4;,%)QP3AE[ M19H'(9\N,3DH:N*@.(\L(5T(F@D=W$"X%O/;"(4QS3\1R\3@Q3B;'[_./O[] M!"WBDX!Z(:8)0==,^B/&[<^-YE1WR"*$Z(ATI$V7^_:XHA ME'B@4"*G>L"7,L:`K\(H&GR:'WQ_@=DR^VK(ELZ(K==QL`@1X)]1<(W!%0JY M@<&,_?$\OA]MQ2L/:$(\@(F/2+;8%\<'B9=_P'Y4R)JU&'F8S=[K>)"++;HO M"5ZIM9TSQWHZ'#T-LJ[0'8H21!N@M/G:&#ME1B9@R6BYAH3R$,NFKU=F6UM3 MY`UO\-W(1P$W\RO^`[?NJX)UV4>_3Z,XB!]GR2(,O-,0P[ADG/HVG>TL96EB M[)0H2*D"0=85PTO'G%M?0\_]_;F?16S+@F@\?5BCB);MV-3*^(^_@:T)+'*2 M`*4TJ2N@4(RY/"E(==T?,'Y$$2(PG$3^Q%\%44!CPO9^=T@.%%4O8^!HBF4" MI(P%@)$/X`X3UQ"EJ8PRPEH9J3_$'6,:4R94)@:=++A@7GF94C8WQIA*$!-P M"=H"6ODT]J8F2)G,Y]/KN6O@J!]G M&1(R[?;IVWAXA:[APPPS-^M1M4MN;&[!VY$+8N;V<-J`$4?T.4@9N`8:U?BK M+I".)?H#T@6*CR&]G1%\%_C(/WK\1)%_%IT&$8R\(+J9>&SY#.)`N69U(&0, MON["&ZUSC"58AOB>`HX%L,S9`;CAY]S*UUU5902;&KH_;$\AB9A`=(;(_!82 M=`1IX+'5_"0(DQCY#4!6]3)&K:98)A`5)(4KYJ=$081B$&+JW,Y14QEE$+8R M4I]^_FJ%HWG,)O2?89@T;24KS2SX]?6,S?QY3A-03M0UV#2-M^K`RS3=(S#8 MC-D$!OZ5.0`*#$P7-^>,71A;Q<`5[?5GU'FRH.BO!$7Q]([]0U5>>'-[8_,K M13'.5_UC"+9,0,K%-:`HM5!&CZ9%>DQ^5K-E"K];UL,\":H6QQ18SH%(8\R5 M/*>N#?H#TB^(UV0A?W*'"+Q!%\EJ@2]R1F#'\S`9A MU8%V#:5FJBD#V(:!W<`V+8BKF#E;D]DKGF6"FR`YYPE@RA10P0W@+;O/"=LR M-;5!M=K`/4;U?3_@M:<.F#D`:?O$DA4.B@B1<\*_:U#GRBZ7$YI'*R8$$U5DJ5&QJM./5,3J#"* M`"_!AJ:KJY+--U`P=":=UT$Y.:`Z&Z\[RDYA0$38G3G= MB-P%'J+;M&%6Z,[KW(/*;-.VMQ':.HAI@CC.#MQQ?GR:HAE'L,Y8\N-X)#L$ ML$ZYNH2^#LHJ(K"S4??K1/^,PR2*(4G]MC(:F]M9<*0;6%MPI3>44Z?:&1@I MQUYUIZ5Z[SY!33R/)+QZ8:4-+ M_SV&;#P/,T#2&7R$BQ!=$^BC;"EM"MM(>IB';M3B&())D&?KD:`/!B#F+%S! M4@LU5`(XNF;9U_IS@KUDM=D%IB=G3]EG=6M09Z?:V4.VF+ M:%SLR_/`XH<"+U>C2JTT4U=-U=)Z+I:J-V"S!8$>2].MH?1&G'V+TPA"75&Z M:U!MKZ/NM>A]+LR%HM-*KKEQ=99VLK!$ZPAE89W.BH8%G^<@Y00NW:LU:*>8 MZI*M;ZX]8XU-T`2&9Y&/'CZBYOQON9T-1-6SM@&BE#(0I`&C[2!JZ@=?`Q29 MXITY"Z,HE=+MO>^S,383/]4S,FM$TNHH`%C>EJ>FGGJ.B@QF][B MD.F4*8P)^(K4_P[7F/X3^&@9>`&*O$?G8*?61:6P7M,R MW4/WA!EY(7547@15K8U"^!IBF)W!VEX1%C'ZSW=2@\ZLBYJ:*`;TM2W2 M]^T*>49@:M<==?P2#5?9]1B?LLA\!65K81C=B/ M'EIMXR9Z<;/69"Q$*+H);G2CPVK-3,7+'JZ0QSB%CVD0UP=;4=C>D3EED/@. MQBNZ::P:M3"Q];[VDQ,F@"^2&B&L"U/L?F^T?ZQE992@S`D"3M$5W#0.M;A+ ME*AUWRG'S?7"#57"]>VLI!IK65M),V;Y11=K@Z6#KTLO2A3?[YT&02QF)YX: MP&+68MN4`%']:WI;$K%R'T)[H8T/27\W!`7.:=ZHR-L5-)JIJ>Z2A:[&??+T MT>6:)TTLW'0D([2O=)*&\#9O.L(YN\_PIB,-56EFE[0-_921,^V(V3XB93:P M)VZX!S5QLI--G,PUY#4K0AT>ZS-G=(5NQ,6H47P!5W6.7VTS"QFC>L86$D9; MPH!3=@48JI%7LT4RG?=Y4?XV&'?-A*%\NL=1"W^O#04+U^VW%M?8TWL]W'VI M`109NX(_`P55[_/O:-#^4,NS6?1RN0VM-&"SVLX8@8VLC7%V.`2".(^9S9@D MS,D6[U2Y!K%\!I-"^04*(%ZU%_N4RW377)8%*+D%VOLG%8TT&ZI,?UFUI]CYOL/DCH6D$ MZ!I?(:Z?($1L_YQ>=WV.*?O<3O1E+ZPLW)VS/P687;RSD0O$&)!#Z4RR67^)2']I0U5I(N%F)':H', MZJPR^L*!%HZ*X.$:H'7T4`TBZ5JF/X"=!W`1A"G6(U\[+*GL9@PT7<',0Y8% M3L)3^:Q"F+IJ*F.QG0%[3/K`."'HM&ED;AP6&`_!]2T2 M#W/#R#D4-0^\DF)1J/WIGNAJ3&27FEE_DLO>3.15'N1R#2A-8U>]P_5T@?$8 M!A';;V6%]&S[E:P2$1E-Y_0F+TJCHX4PN*YPAG=!Y%2SDG5GGBAMKXAJE+N= MF9[$L=(K4)9TL.E,[;%4N<#%N0VH6@,2#\EJY7+;HK]K1K8FY;OSM942OR(C M*Y5]G*`K.&@::%T57U6EW0/*.4V^%HJ$\5FTQ&0E7"?)I8U:W8Q"QFT$LX(& M[M9DV?\"*V#H%@`#(.KN"QNTKJWLSI8L`GO[]&9/;*296F;5X;$ONZ MS48JL)&'=AWQZRD93+)[Z= MJ%F9-3H9K2E@GO'%$%BPTG5X#63B_%E;FMM5RL;F\*@.H3Z+&: MWB&NHPAM6XA;TH:[@EZAJ$:L8K"4LX M``+Y%;HU#?<0RK(8?\\"69\'0A07Y:J4;W`)MW\'F:!B4]7_)R_7['A!0K,7+T?)6E40`MJTET#36U`ZUQMIN4VQ\*9HP68HNS7WCQ MOAX+=2V-$2%A;Q9=R,@"RNFZ!@_)J,L@46J]NQ=U!$.^@LYOD?S]KOIV1OZ1 ME+6)X3/"(*7LBMV50RXZ-AKJ[F[SYJJ[;86A!`JMNALAI(N@)L`Y/YL7XRO9KG-9C3T[/CL^G%\6\NX:J+HHIPZV[2'A>I MW=NM%'4L3:W-%RNY&$8+%B?MX&Y?,>3*:J6C>K,#FT?H)HAXJ97BV&:UG?'A MS4;6%HYP+G+:^SG(:21Z*LX\9MOI(ICG8V:*!_N5`#HR1,U9]$=HB:) MFCH"^TK42(0U_N/)SZ$%.8_/+T4C48]FBD9I3!?QVNW:+!FA'O&[SVNSZJ#L M3*&:N:JZ8_JI/=&=BX0;8+O;QNX%S_933>GUSJYAJW;0TEN=>WU")65YA=:8 M<'SR%>"J M7M8?5]G#!=\Y"WX-[^8M*,[+U8R0IDY4+ZD8W]A=OT5F2VE-/J?XC=$VN$3> M1NX&_'?\/UM;W0[BQ8A0U+2M=2V_5#/&XK:UUL3=L;2]"J%XW%82'E9T,$*> MGC#V;G[8\G#)^'I:*&*BC4WZ]J.E#K0MS]F>RSQQV%66^\A/\3#Y;P@2O6?) MMRTM/DI>86_E#%GV)#DG[OJ#Y!4%-#]'7C)`<4SG["?V6?X1^V_N[72`.-3%9'*T@SGMOGW[ MYK#;W_G]WS__]/X?W6YGR*CK.^!V1HO.^=F'XVON8P$=3L?B'C%XU3EVYX@H M@5,ZG?D"6&=`")TC(4?@K^0_SNXK^=ELP?#D3G3^>?JOSO[>WMON_E[_3>>_ MP^&?G]Y^[!]^[!\O^QX/A_W8[]_?WN^!.$`M&VW7HM-/M*I4\3+Z_ M4S]&B$-'&D/XTCW5Z&'$O%W*)CTYQD%O)?CRYY]>O`B$WSUP'&MP M?[`2[_?^_'1YX]S!%'4QX4)9%3;D^!T/KE]2)[#+8,B.5D+]UUV)==6E;G^_ M>]#??>!N1-$Q]AZ'F:(14B#T%&A[!P?]B)SJJ2`$:TV6(/0/#P][P:=1:=F= M*Q[%H[V_Z84?)J1QACJ/P$HR7X1L,NK!-8P[ZO>7ZX'>Z)Z2Z&&7?3NCCC\% M(E:_CXE[3@06BP$94S8-.'K9"2QY)Q8S.'K)\73FP>K:'8/QT4LU0'?5N4+_ M%^.^>T_JSQAP*19^Y8UQ/&("X8K'0R/PCG:,F_6*JAB]R3@XNQ,Z[[F`%4*OU1]* M_=?=O?[277Z1E[Z%PU_#!*M1B?B,II!06"L653!*Y#&+*XN8L^I2_AFPN*.] MQY<2O9F,CT1TG3OLN:O68T:G!0!<*4$S;.CX7&I#9ZHA\G8ZE+G`PMA>"_XK M0VYEMRFXQSZV#.^X:>DX[]>-\Q`8IM(&]PR)+,#C/2H7Y=%]2AVJ=2'8:\@9Q#'S["0AO6DW*60:\Q-IV" M-W51<.HS9>@%Y@[R_@.(Z6..5M0R(O0FIW/Q:\WN0*=32FX$=;[?W$GC^94O MU'I:;=_TOI'5R#)^3&!(9^JW>ID:^B,/.Q<>1*CX'[V>7>"T"R`HP>>X*LK M@;H1EUQ>_G;,N5Y;C5"#3IB)L?(ZG5T5Y="W!7ZYKC3"/REK#PUK5E:4:=^< MC5/$[S3@!Q_9@'5H0T49]))N=),;W`JP$U95E$S?%O5,N"W"N=14>?KL?8G1 M"'M88.!RA1?D'N^H)T?A9S#&P9N"+8U%1YGSS>S^BOMG\FM&@ MS529V%M1LGR+P.0XU">"#]$"C3RX9"9N-2]9]E65^BZ%A7SX;<.]N@SWYH!'5\[G?_M8Z'80!@ULH"/+WKQ\=_WL M#&5?()TUW.#\@3P_6?F4)6D#'ZD6:HC8NNILB^3;4[E/%@MK8C90L&Z;!O\& M]\O'KHM#=88(RW7T*9IAH71+WXYII&U@0VNIAI0&]\G7(!`FX)XC1C"9<+G> M\Z=^L,P+DS"Z.<2@H0U4F=BO86WKFK0R9WSCF=X*5M+LT["P=7%:*0O=1/XR MDY/<9C8PE&^[YN';7F.5!ZJ8#E29!+\:7\V`A4=+*RE!T`S5:"V"1J=R,B?I MG6<\R,AIT-AL.`?B:_>MCQ\WZ*%F2,>GN)51K:M..*5Z=?4*'V0484!WBDEP7%3@.2Q5U]"4U\HJMG(A:%TE1.()A8:DI)15 MI*R9V+K"B*23&T8TNVA8-[*BHX:;\_`9A%S[T"E<4JXC(2YC%0,)\UI7([': M5@^!!4?L3A#'CKQCSK#GRRUVSGQOVMHJRHPA:5U-18[FFY'X0Y%7V?'%S4G[ M"NI]2?*^FDO[)O#9GXZ`78W7#KSFN&+A;JRBM3A(%9V4K(;GB`5F/KMA9S\, MYUF`Y96A-)K74L79%QZ]KSZM]312:[):3RHUE95?ZA)1)?=)?$:3YI;,2I8>A/_EG;37JRFRP"DUN47S1=@6Z]1;2%W$VA:EVK4*#\@<^!E[$&R.OHQ>,Z$JG59 M2G,CMN;YQ^6WA5E)C?(7F""Y"M_>C[,Z^C%XSH2J^B-Q4AW'`39PN9FT#3ON-U2G6Y-E>_5*GM''DJ MLQ&^]"NYJ-=5G13IPC)RB\%3YF$^S>%MJ<@)3#!1SXVOQJ$B*3$S7\$Z-_>@?J**$06&W\UC[;#RK^/1SMR,W/)DSZWTJ03.=+WG'5X5HNF M5CI(2'6BC_UU*YIUP88]V0#_V,(EQ=*Z[7V5-5>/;YC8U8PKE\DK3^;3)Z.;L\.,7.QAWU=>+E63S^ MOJ9R?#9OD'K=-T^;9T_>W`@8B12U=`9HI.WR:JW-C?OVF^AM?4)AY6,*L5-@Z4'$`=# M28$@VWRL9%L31)OJ7+V^7,&78W[K=IV:M?F47*9Z#;W5-5#"-"#HI!L*!G$\-3HGA!IV^QR\HRZ?M*Z5 M?JXI4ZG)WXU&;][OC=1\]O^R2LCB2A:K'4NTM2=:&&+1RB`2.0VW+%Y$WH!( M6X-O`ZTMFA13H_FP4DS?Y_A26'DC@#6FF+6U)[X88M'*^!)YV]'R!?/JY2AU MA16CT9N/)D9J/@>1PLHG7[5EMCS):V5/X,BUOY4A(WRGPBUZJ"]YH1^R^>"@ MU^TY(A16_A%,LU"@%;J8:8 MRVL("H55:4&P**SS^3]02P,$%`````@`8WNN1@Q8Y[P1!P``DC,``!$`'`!M86)A+3(P M,34P,S,Q+GAS9%54"0`#"O=450KW5%5U>`L``00E#@``!#D!``#M&MMNVS;T MN0/V#UQ>U`*1Y$N2)H'=PDFHS^[':_?3G]7#W[7*W7 MCVZ__%'[7._^Y:#'QT>'^$,L##?'XR&R;2V2]$8DQ`BT8+)IC90:G[NNAGZL M.UP,72!==;]]N>D9."L&/(^D/<1XG"$,L.P;\&3#U<+8E:I=KZ8H`QIDX"'N M8RV#`:O49T`^H1G04U\$CB2>,^03%S8T\-$\S:>`LK]725T].SMSS6X&"M1\ M-4\\T>_8C34^!;"2@G:!^>8`XC8#`1L^Z:!P7&4<1R]A/5X M3-F`F\6;AI;N/!7QG@R0.;!S-1V3YH&DX3@@!\F[D2"#YH$^!CL]@N]C01Q0 M*P41/`"TM:KI;1=0)&AE)+J9,4Y)8.$M45DR*!#A8R(4)3([WP/W=53RR6!3 ME0"%,KJK"@6XOZE"@$*"7=3%P\&FN@"*%P7_LKMI&@^@`](/7^\[&;VEK!$+ M17WQ_8I*+^`R$N26*W("F3ZD2@>\;#'_DC,%Y0/*"#`]0-1O'FR($XN7R#?S MT`\52.:5"K+1C!8L-#ETXJ`<1829KC\YF@UWD5B>1R2)?\<^F.?%($\P$Y!U M6/-Q5`YGP;PKD))7J8E>UVRU3QR.!T[)(X*ML],\4(%A*B>K#5-SD"&!$AI[ M0RR=4=S55YNW M[B###?$!RO,[1YI5'(?Z(]Z*^)#\B4+8]T;&TSMK+@$5F MK*XVXWL'S**4B:Y,H+*RJ[S>+L+UY2AWY-:;B=QQ$Y&YP31FTK!0' M'6A>112^K,QN1K@H)H\V3:V:-3*\]5[&'>78[Y-L&8>I/HR(_G:%V72=Z?,@ M1=&[ICY6'00$4$)A;P(XWU9(!/4PNZ`<.C:BJ-<#_X2.07:8UP.5S?003FN;.:UCMK5LJ<78@%#QU M-[@G'KP*IATI(^*W/(]'IHN'XV4^%K[<)BMO3KPH,V]8DL]1S%Z_3P5`L01H M)@+*9-@GYR+?.;KD;**_9_4#LY8/_)Z`.,3O8J'6)NSGT(KRP>EJ>Q_I+TX9 M4?-.H@>.$KK($-Y;4)N">^;^D?YO,;\-3J^F'3;@(ER\,)>!+K)7W,TDV/E' M_3$B)H5RM/8F>JZ$7N!`_ZK3&Q&BRI;=>9PB<]6V*K<)?10SV-MP*>,=Y_/; M@\!,0@W2/\&N2Y'K$8JL=[8Z.1X[\WD0Y0GNK57JUO)50A?9EHI"GB(OZ$D+ MZ11==&J;7G2`DWZ9\=KWFR]L=N[&1."%J-T&N2B"ZZ_0[LQ8[>U;KB-A@$D> M\--+`GL]D:*H7O,[74'[8M@@P^=_'=$--S=@`HNYZ9,&#<=<*!0/'-UPS^P4 M#,/HE9U.Q-CZE5VMV?6J\R1]"[&E(9V"<1IW4P%\)5P]E^"RR`2S9G^FV5=/ M2K%?Q'^)!)S=OE0(SNRM!Q7CE1-<=M&:=P;&R-<(;/2D27!$JF M;^P9J5CB9T0IG#8K$F411S_8,^0\\V2H"^&^5`+NR8'FMJ>X]_>(!SX1\@IRG:FT MTT6]-L.95[=(O9!#@<=B^@(%XS2ETJU^;(&FY0GB4S53N^5YP-[O,$6@$*CV MTY@P262JX=KMG51FX7M2OG=*%2H$V4FEDM%=>2UX"%YF+((#>161^<]EFZAY@4;'GH,H[J$\\:/>"5]7AEJ@;+K/"E"L* M;VGPGVO"93&3WV!D%T^U(&D>(_YB@=H*]>=J"Z[F><0W"3J?D"^X$/Q1#V*E MRI6!_"]UR4I65G"Q'%V0(65Z?@SZ8`.;E=K5FS]=X#;S5XDZ]UH+V7#C*SH\ M_@-02P$"'@,4````"`!C>ZY&D;&"P``$0`8```````!````I($` M````;6%B82TR,#$U,#,S,2YX;6Q55`4``PKW5%5U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`!C>ZY&>@J$&UL550%``,*]U15=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`8WNN1BJR>+'G`P``"AX``!4`&````````0```*2!5AP` M`&UA8F$M,C`Q-3`S,S%?9&5F+GAM;%54!0`#"O=4575X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`&-[KD:6N&=#`A```#Z^```5`!@```````$```"D@8P@ M``!M86)A+3(P,34P,S,Q7VQA8BYX;6Q55`4``PKW5%5U>`L``00E#@``!#D! M``!02P$"'@,4````"`!C>ZY&/T3W[R<+``!:G@``%0`8```````!````I('= M,```;6%B82TR,#$U,#,S,5]P&UL550%``,*]U15=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`8WNN1@Q8Y[P1!P``DC,``!$`&````````0```*2! M4SP``&UA8F$M,C`Q-3`S,S$N>'-D550%``,*]U15=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(``*]#```````` ` end XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Impact of Recently Issued Accounting Standards

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

XML 22 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information (USD $)
 3 Months Ended
Mar. 31, 2015
Jun. 30, 2014
Document and Entity Information:    
Entity Registrant Name American Biogenetic Sciences Inc.  
Document Type 10-Q  
Document Period End Date Mar. 31, 2015  
Amendment Flag false  
Entity Central Index Key 0000856984  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding 1,088,740dei_EntityCommonStockSharesOutstanding  
Entity Public Float   $ 54,242dei_EntityPublicFloat
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q1  
XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
American Biogenetic Sciences, Inc. - Statements of Cash Flows (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Statements of Cash Flows    
Net loss (10,577)fil_NetLoss (10,324)fil_NetLoss
Fair value of services provided by related parties 0fil_FairValueOfServicesProvidedByRelatedParties 5,000fil_FairValueOfServicesProvidedByRelatedParties
Increase (decrease) in accounts payable and accrued expenses 839fil_IncreaseDecreaseInAccountsPayableAndAccruedExpenses 5,324fil_IncreaseDecreaseInAccountsPayableAndAccruedExpenses
Cash flows used by operating activities $ (9,738)us-gaap_NetCashProvidedByUsedInOperatingActivities $ 0us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash used in investing activities 0us-gaap_NetCashProvidedByUsedInInvestingActivities 0us-gaap_NetCashProvidedByUsedInInvestingActivities
Procceds from related party borrowings 9,738fil_ProccedsFromRelatedPartyBorrowings 0fil_ProccedsFromRelatedPartyBorrowings
Cash generated by financing activities 9,738us-gaap_NetCashProvidedByUsedInFinancingActivities 0us-gaap_NetCashProvidedByUsedInFinancingActivities
Change in cash $ 0us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease $ 0us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash - beginning of period 0fil_CashBeginningOfPeriod 0fil_CashBeginningOfPeriod
Cash - end of period 0fil_CashEndOfPeriod 0fil_CashEndOfPeriod
XML 24 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Use of Estimates, Policy (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Use of Estimates, Policy

Use of Estimates:   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 7. Subsequent Events
 3 Months Ended
Mar. 31, 2015
Notes  
Note 7. Subsequent Events

Note 7. Subsequent Events

The Company evaluated its March 31, 2015 financial statements for subsequent events, through May 14, 2015, the date the financial statements were issued and there were no subsequent events that will affect the March 31, 2015 financial statements.
XML 26 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Earnings Per Common Share, Policy

Earnings per Common Share:   Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2015 or 2014.
XML 27 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Cash and Cash Equivalents, Policy

Cash and Cash Equivalents:   For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.
XML 28 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Fair Value of Financial Instruments, Policy

Fair Value of Financial Instruments:   ASC # 825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.
XML 29 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 3. Basis of Presentation: Income Taxes, Policy (Policies)
 3 Months Ended
Mar. 31, 2015
Policies  
Income Taxes, Policy

Income Taxes:   The Company accounts for income taxes in accordance with ASC # 740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

ASC 740 also clarifies the accounting for uncertainty in tax positions. This guidance prescribes a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination. If the tax position is deemed “more-likely-than-not” to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain tax positions taken by the Company on its tax returns. Tax years subsequent to 2005 remain open to examination by U.S. federal and state tax jurisdictions.

Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2015 and 2014. The Company has net operating losses of about $470,043, which begin to expire in 2026.
XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 1. The Company
 3 Months Ended
Mar. 31, 2015
Notes  
Note 1. The Company

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or "ABS") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court. On August 13, 2010, the Company’s sole officer/director transferred and assigned his control stock position to an unrelated third party but remained as the Company’s sole executive officer/director.

XML 31 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 6. Commitments and Contingencies
 3 Months Ended
Mar. 31, 2015
Notes  
Note 6. Commitments and Contingencies

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of March 31, 2015. The Company has no non-cancellable operating leases.
XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 7 59 1 true 0 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://maba.com/20150331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Sheet http://maba.com/20150331/role/idr_AmericanBiogeneticSciencesIncBalanceSheets American Biogenetic Sciences, Inc. - Balance Sheets false false R3.htm 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations Sheet http://maba.com/20150331/role/idr_AmericanBiogeneticSciencesIncStatementsOfOperations American Biogenetic Sciences, Inc. - Statements of Operations false false R4.htm 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows Sheet http://maba.com/20150331/role/idr_AmericanBiogeneticSciencesIncStatementsOfCashFlows American Biogenetic Sciences, Inc. - Statements of Cash Flows false false R5.htm 000050 - Disclosure - Note 1. The Company Sheet http://maba.com/20150331/role/idr_DisclosureNote1TheCompany Note 1. The Company false false R6.htm 000060 - Disclosure - Note 2. Going Concern Sheet http://maba.com/20150331/role/idr_DisclosureNote2GoingConcern Note 2. Going Concern false false R7.htm 000070 - Disclosure - Note 3. Basis of Presentation Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentation Note 3. Basis of Presentation false false R8.htm 000080 - Disclosure - Note 4. Convertible Notes To Related Party Notes http://maba.com/20150331/role/idr_DisclosureNote4ConvertibleNotesToRelatedParty Note 4. Convertible Notes To Related Party false false R9.htm 000090 - Disclosure - Note 5. Related Party Transactions Sheet http://maba.com/20150331/role/idr_DisclosureNote5RelatedPartyTransactions Note 5. Related Party Transactions false false R10.htm 000100 - Disclosure - Note 6. Commitments and Contingencies Sheet http://maba.com/20150331/role/idr_DisclosureNote6CommitmentsAndContingencies Note 6. Commitments and Contingencies false false R11.htm 000110 - Disclosure - Note 7. Subsequent Events Sheet http://maba.com/20150331/role/idr_DisclosureNote7SubsequentEvents Note 7. Subsequent Events false false R12.htm 000120 - Disclosure - Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationUseOfEstimatesPolicyPolicies Note 3. Basis of Presentation: Use of Estimates, Policy (Policies) false false R13.htm 000130 - Disclosure - Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationCashAndCashEquivalentsPolicyPolicies Note 3. Basis of Presentation: Cash and Cash Equivalents, Policy (Policies) false false R14.htm 000140 - Disclosure - Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationFairValueOfFinancialInstrumentsPolicyPolicies Note 3. Basis of Presentation: Fair Value of Financial Instruments, Policy (Policies) false false R15.htm 000150 - Disclosure - Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationEarningsPerCommonSharePolicyPolicies Note 3. Basis of Presentation: Earnings Per Common Share, Policy (Policies) false false R16.htm 000160 - Disclosure - Note 3. Basis of Presentation: Income Taxes, Policy (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationIncomeTaxesPolicyPolicies Note 3. Basis of Presentation: Income Taxes, Policy (Policies) false false R17.htm 000170 - Disclosure - Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards (Policies) Sheet http://maba.com/20150331/role/idr_DisclosureNote3BasisOfPresentationImpactOfRecentlyIssuedAccountingStandardsPolicies Note 3. Basis of Presentation: Impact of Recently Issued Accounting Standards (Policies) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Process Flow-Through: 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations Process Flow-Through: 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows maba-20150331.xml maba-20150331.xsd maba-20150331_cal.xml maba-20150331_def.xml maba-20150331_lab.xml maba-20150331_pre.xml true true